initi coverag larg cap biotechnolog sector
posit view despit uptick vs concern
drug price phase failur concern growth larg cap
stock weigh sentiment smid cap catalyst-driven name appear
interest specialist investor still ytd biotech subsector
 second worst perform healthcar
vertic healthcar servic perform wors broader
driven out-performance tech industri telecom
energi backdrop think investor need
discern select stock gener alphawhen look larg
smid cap name view buy broad bucket biopharma stock
unlik gener alpha seen
respect vs broader
becom sector stock pick support rigor analysi
best way gener outsiz return believ alpha still
found examin stock three lens coin target
therapi portfolio discuss initi larg cap
sector outlook rest
host confer call tomorrow tuesday may
target therapy- approach find alpha take target
approach pick stock look coverag via three main lens
strength current commerci busi pipelin prospect
impact potenti either buyer seller
top pick vertex neurocrin appli methodolog vertex
top pick among larg cap biotech name think vertex
best growth profil biopharma although share may seem expens
price-to-earnings basi peg-basi under-valued rel peer
view also like neurocrin smid-cap space due growth profil
ingrezza rel strength pipelin
cautiou rate share under-perform due
view compani core base busi could declin near-term
also think current pipelin remain weak follow late-stag
failur aducanumab alzheim diseas share trade
discount peer forward price-to-earnings vs larg cap biotech
could see multipl compress without
transform strengthen pipelin manag current strategi
increas share repurchas may support share near-term howev
benefit like temporari absent large-scal
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
tabl content
fda still pois product innov despit departur
drug pricingth overhang like remain elect
area watch across coverag broader
allergi immunolog
genom manipul gene therapi gene edit
biosimilar innov headwind innov sourc revenu
holt analysi support macro view
medic meet
launch coverag larg cap biotechnolog sector posit view
launch coverag transfer
coverag vamil divan also see industri analysi
top pick vertex neurocrin among larg cap name think vertex
best revenu earn growth profil one-year forward price-to-earnings basi
share appear expens much higher group mean
look growth share underpr forward basi
share appear rel inexpens versu peer multipl broader
larg cap biotech group price major pharma price
price like long-term cash-flow gener cystic fibrosi
franchis view grow late compani also
promis early-stag pipelin current reflect number posit
updat earlier-stag asset could drive share upsid
also like neurocrin top smid-cap pick believ compani main
commerci asset ingrezza continu drive revenu growth view ingrezza
best-in-class treatment tardiv dyskinesia td like continu
prescrib therapeut condit later-stag pipelin could provid addit
revenu near-term updat earlier-stag pipelin like provid
share upsid get increment updat
out-of-consensu call biogen under-perform cautiou
given believ declin base-busi underappreci
competit threat ms sma franchis especi concern
soon-to-b launch gene therapi zolgensma could take share sma incid
market earlier-stag asset ptc/roch risdiplam could also take share
preval market recent commentari manag priorit share repurchas
larger-scal concern us may support share price near-
term repurchas noth address broader pipelin concern multipl
recent low could see compress absent clear strategi return
growth think need engag transform help
revers current cours
rel rank among rate band outperform-r name rank vertex
neurocrin first top pick larg cap smid cap biotech respect
aimmun among neutral-r stock posit gilead
think deal could help expand multipl hiv busi strong
gilead rank ahead regeneron think strong base-
busi could see eventu upsid pipelin concern
regeneron neutral-r stock given eylea headwind high expect
sanofi collabor includ rel rank figur
proprietari work support these support launch conduct three
proprietari physician survey cover multipl sclerosi ms asthma hiv
work support thesi ms regeneron asthma gilead
hiv also believ model approach vertex uniqu quantifi
opportun uk franc two key countri high preval cystic
fibrosi vertex therapi reimburs govern payer
outlin scenario allow user model chang assumpt price launch
time product get reimburs support thesi conduct
 cash accretion/dilut analysi potenti acquisit target also analyz
impact potenti competitor spinal muscular atrophi sma space
mostli result enough improv sentiment among
cover compani commerci revenu exclud aimmun five six beat
earn four six beat revenu regeneron largest earn miss
indic difficulti model collabor sanofi key point
discuss initi also think on-going launch dupix asthma may
challeng investor hope despit much better profil vs
competitor headwind eylea franchis also mount near-term
launch direct competitor sinc april share vs flat
declin drg index declin ibb etf declin
xbi etf figur overview earn perform
sentiment remain mix growth concern drug price larg
appear better despit would character pretti good earn
get sens sentiment healthcar remain poor biotech servic
worst sub-sector perform hc see figur expect drug price
broader discuss healthcar reform remain overhang
elect yet see concret action drug price think
polit appetit reform medicar part could see elimin
revenueep consensusactu deltaconsensusactu non-gaap except charl martineau univers toronto
rebat safe harbor protect medicar part plan manag allow
receiv rebat manufactur without violat feder anti-kickback statut
see global pharma/biotech recent piec us drug rebat could
also see part drug reimburs price base intern price index
uncertainti point broader price pressur large-cap biotech pharma
could bifurc stock base compani abil drive revenu growth volum
pipelin success vs price increas
recent phase failur also contribut sentiment highlight gilead
selonsertib trial examin drug patient
advanc nash phase trial aducanumab engag
emerg stop earli due predict futil result aducanumab
discontinu primari caus share price depreci
ytd think neg trial result reinforc develop
riski real possibl late-stag failur even larg cap biotech compani
target therapi approach analyz coverag univers think
investor need select invest biotechnolog stock gone
day buy basket major biotech name would gener alpha
think look compani via three lens investor select
stock best upsid potenti first view compani current
commerci busi whether grow declin remain flat second
view pipelin believ compani lead project
pipelin revenu might alter growth profil compani long-term final
look prospect compani either buyer strong weak
posit acquisit target also strong weak posit although
believ basket approach way gener alpha generalist still
screen base revenu growth rate near-term longer-termlook
current commerci busi pipelin rel price either price-to-earnings
potenti upsideal align target therapi analysi
 like remain driver sector near-term follow
announc bristol myers/celgen mega merger begin
investor interest remain high current track higher total
aggreg deal valu cours vs prior year think group
larg cap biotech major us pharma european pharma continu engag
 broaden pipelin enhanc earn across larg cap biotech
compani see signific capac transact think gilead
need engag larger-scal help grow pipelin nearer-term growth
profil manag taken recent stanc focus share
repurchas gilead new ceo openli discuss need acquir
vertex lesser extent regeneron less need deal
drug price health polici overhang elect
previous discuss drug price rhetor weigh neg sector
presidenti elect come focu think discuss drug price
continu side polit aisl could see action rebat reform
use intern price index prior elect expect
talk drug price potenti medicar key compon mani
democrat presidenti candid platform balanc
recent discuss gilead use nih patent cover use truvada prep
also present headlin risk view unlik significantli alter revenu
estim believ govern would use sort march
right bayh-dol act essenti invalid patent result feder
fund research allow gener entrant undercut brand product price
fda product remain high nda/bla biosimilar fda
front expect environ balanc need industri effici drug
approv patient health safeti former commission scott gottlieb
saw approv gene therapi clariti path biosimilar overal
coordin industri agenc think act commission ned
sharpless take approach continu push innov open
exampl think agenc urgenc reduc roadblock could help gilead win
approv filgotinib without requir manta male testicular safeti studi
total posit finch trial drug price healthcar polici remain
overhang current fda posit factor sector broader biopharma
area watch across sector identifi five therapeut
area ta watch next year expect innov ta also
watch respect commerci stori asset class
allergi immunolog led recent launch regeneron/sanofi
dupix treatment atop dermat ad asthma
expect continu innov allerg immunolog diseas next
year asset gilead filgotinib topic ruxolitinib could
repres next leg innov space also could see first
approv treatment peanut allergi aimmun late
novel oncolog expect continu progress novel oncolog therapeut
bispecif allogen car-t
malign could potenti replac autolog car-t therapi
also could see novel therapeut use solid tumor prostat
lung beyond bispecif allogen car-t small molecul target
therapi like becom import see initi clinic data
oral kra inhibitor clinic data/approv novartis/incyt
inhibitor incyt fgfr inhibitor
novel neuroscience/centr nervou therapi broad area
import area growth broader biopharma sector biogen
aducanumab signific disappoint investor research
patientsneurolog diseas remain area high research invest
expect continu progress sma novarti gene therapi zolgensma
ptc/roch risdiplam could disrupt biogen spinraza busi
also interest neurocrin recent foray gene therapi treat
parkinson diseas pd fredric ataxia whole think continu
updat therapeut treat neurolog diseas could impact sector
next year
migrain technic subset think migrain remain
area watch commerci point view next year amgen
novel migrain drug aimovig appear struggl poorer-than-expect
sale close watch novel migrain class competit
price pressur could reduc estim near-term despit
pressur think like remain leader anti-
genom manipul gene therapi gene edit recent high-profil
deal even approv genom manipul space includ
therapeut area one watch come year
consid cover compani leader space note three
program could provid pipelin upsid next year biogen
recent acquir nightstar therapeut gain access mid-clin stage
retin diseas asset section therapeut discuss
emerg competit biogen spinraza novarti gene therapi
zolgensma highlight potenti disrupt natur gene therapi
product discuss could benefit potenti
acquisit sareptawith gene therapi platform muscular dystrophi
biosimilar hereamgen biogen like player space
coverag univers two compani expand biosimilar busi amgen
via samsung bioepi jv think posit stronger rel
much broader approach biosimilar product
across immunolog oncolog rare diseas vs anti-tnf portfolio amgen
pursu commerci ww wherea current plan europ
wholli own biosimilar franchis wherea share profit via
samsung bioepi joint ventur inde think biosimilar busi
help maintain grow revenu base face current revenu eros
biosimilar franchis impact biosimilar repres
innov sourc revenu tradit innov biotech compani
biosimilar yet take us think polici chang includ
prohibit rebat bundl potenti long-term chang medicar part
could help increas util product polit seem mount
bring lower-cost altern market sooner
overal remain posit
larg cap biotech sector
acknowledg address headwind think alpha gener remain
possibl howev captur systemat thought approach requir
investor next section discuss way think sector
coverag univers use target therapi approach approach streamlin
look believ core compon compani invest
thesi current commerci busi pipelin posit
acquir target either posit rel strength weak support
analysi rigor model dive deep scienc solid
understand around polici macro issu impact compani
target therapi approach analyz larg cap biotechnolog sector
launch coverag larg cap biotech name broke compani
three area analysi current commerci busi pipelin prospect
 posit appli framework across coverag help investor better
determin invest version target therapi portfolio think
take thought analyt approach investor gener alphaeven
environ sentiment poor unlik return glori
day buy sector gener outsiz return
discrimin invest henc outperform four name vertex
neurocrin aimmun neutral three gilead regeneron
under-perform rate figur rel view coverag
univers use target therapi approach highlight out-of-
consensu call under-perform support three-part
analysi look current commerci busi pipelin prospect
figur target therapi rel analysi coverag univers
regeneron pipelin revenu gener subject collabor profit share agreement increment end-us sale necessarili get book revenu regeneron
return gener may see concret polici action drug price
next twelv month think long-term polit mount chang
compani coverag longer benefit net price increas
us thesi vertex predic price rather volum growth
increas penetr cf medicin world-wid ww asid modest price
increas kalydeco compani taken price increas orkambi
symdeko sinc launch price taker us benefit
revenuecompanyratingc busi strength total lead biosimilar oncolog migrain tbd allergy/ capac total busi weak total lead multipl sclerosi tbd gene therapi lag capac total busi weak total lead infecti diseas lag nash capac total busi strength total lead cystic fibrosi tbd gene therapi pain capac total busi strength total lead oncolog tbd net total potenti busi strength total lead neurosci tbd gene net total potenti busi strength total lead allergy/immunolog tbd oncologynmnmd ww end-us sale dupix libtayo busi strength total revenuenmnmpipelin lead peanut net total charl martineau univers toronto
increas recent tone chang suggest price increas would
driven cpi asset without invest prior revenu growth us
somewhat driven price increas celgen cover due
impend merger bristol myer known drive ww product revenu
growth partial price increas compani report year/year
growth due price increas
dcf analysi support valuat view backdrop prefer
valu compani use discount cash flow dcf analysi best captur
impact current commerci busi pipelin prospect think
compani possibl acquisit target type analysi also help determin
take-out premium variou scenario discuss multipl forward price-to-earnings
throughout report use addit point comparison determin
rel valuat avoid use multipl pure deriv valuat believ
appli multipl next year earn fail captur nuanc compani
busi discuss detail valuat individu compani report
drive revenu growth time polit side aisl like prevent
manufactur us rais gross price turn realiz net price increas
ou price usual headwind volum growth driver compani
mean innov remain paramount determin compani
gener outsiz return volum new asset real driver growth
think gener alpha biotechnolog stock look
coverag univers break analysi three categori
current commerci busi current commerci busi compani
declin grow remain flat
pipelin prospect assess therapeut area compani lead
lag also assess pipelin alter revenu growth trajectori
compani much pipelin expect make revenu
base time
 posit first assess compani like acquir
asset potenti acquisit target assess compani
posit strength weak assess absolut larg
compani acquir celgen smaller compani acquir
engag bd neurocrin partner voyag
vertex top pick larg cap superior growth profil
rel peer one-year forward price-to-earnings expens compar peer
look basi share rel inexpens expect ratio
expans continu commerci progress made
current commerci busi vertex current commerci busi forecast
grow due on-going launch orkambi symdeko outsid us like
approv tripl combin therapi next year vertex best revenu
growth rate among larg cap biotech univers compound-annual-growth-rate
pipelin prospect vertex strong cystic fibrosi pipelin like approv
tripl combin therapi therapi would enabl vertex
treat cf patient one medicin time see tripl
combin reimburs key territori orkambi symdeko
contribut revenu beyond cf pipelin vertex early-
stage asset pain alpha antitrypsin defici hemoglobinopathi
 posit vertex posit acquir strength note
vertex suffici capac estim transact
need long-term revenu growth
posit due underappreci biosimilar busi pipelin
also like novel oncolog pipelin ascrib valu asset data
remain immatur unlik vertex core base busi declin howev
think compani abl recoup lost revenu biosimilar
franchis drive upsid pipelin success
current commerci busi core base busi declin
compound-annual-growth-rate gener entrant mani drug sensipar broader
competit price headwind other enbrel thesi
predic durabl busi
pipelin prospect like pipelineespeci biosimilar franchis
think could help revers current base-busi growth trajectori
believ biosimilar busi pipelin asset could
make revenu base beyond biosimilar franchis like
novel oncolog pipelin includ revenu asset
 forecast valuat data remain earli
 posit posit acquir strength note
suffici capac estim transact
need long-term revenu growth
among smid-cap name neurocrin top pick due project strong
revenu growth compound-annual-growth-rate name ingrezza addit revenu stream
orilissa solid pipelin
underappreci upsid potenti central nervou system focus pipelin
asset parkinson diseas opicapon gene therapi congenit adren
current commerci busi project neurocrin base grow next
year led ingrezza lesser extent royalti orilissa think
ingrezza could reach peak end user sale orilissa gener
peak royalti
pipelin prospect compani experienc pipelin setback
develop ingrezza tourett syndrom still like pipelin
prospect compani notabl see near-term upsid opicapon
parkinson diseas indic expans orilissa uterin fibroid
think recent collabor voyag develop
gene therapi treatment parkinson diseas friedreich ataxia could
gener addit share upsid clinic data releas
 posit consid neurocrin acquisit target
posit strength given commerci base busi broad pipelin
acquir would expect premium trade price note
compani healthi cash equival balanc nearli
allow compani engag smaller busi develop transact
similar voyag deal ink earlier year
assum coverag aimmun outperform rate like
first market peanut allergi treatment space cure peanut allergi
compani lead product could help increas toler patient
condit late-stag competitor dbt withdrew biolog
licens applic bla peanut allergi product viaskin peanut decemb
think head start advantag combin believ better
efficaci rel viaskin peanut could give aimmun advantag peanut allergi
current commerci busi aimmun current commerci
busi yet approv us european regul
pipelin prospect think pipelin drive near-term revenu upsid
compani lead asset like approv fda late earli
think could gener peak sale beyond
peanut compani also develop treatment egg allergi
plan phase trial expect begin
 posit aimmun posit acquisit target posit
strength like near-term fda approv could see larger biotech
major pharmaceut compani acquir aimmun prior approval/launch
product think remain unmet medic need treatment
given rel flat commerci busi limit pipelin growth prospect rate
gilead share neutral overli neg gilead compani healthi
near-term cash flow support strong dividend current yield ahead
amgen mean major pharma concern
late-stag pipelin thin filgotinib major late-stag asset like new
ceo urgenc fill pipelin gap busi develop need see
execut comfort stock
current commerci busi gilead commerci base busi rel flat
strength hiv driven biktarvi yet off-set gener entrant
europ project gener truvada come hcv declin
expect due price pressur fewer patient start cell therapi
yescarta project grow remain small contributor overal
pipelin prospect asid filgotinib gilead pipelin remain thin
includ credit phase nash asset need see data
atla trial gain confid better understand
asset would test phase program new ceo priorit
need extern bd supplement pipelin see posit
gilead absent detail acquisit execut bd strategi
remain sidelin
 posit gilead posit buyer rel weak
compani need acquiresupport commentari ceoand thu
may pay higher premium get deal done sooner later still
think gilead ampl capac transact capac
neutral regeneron see potenti headwind core us eylea
busi high expect dupix franchis sanofi antibodi
collabor like breadth unpartn pipelin data remain
earli assign concret valu near-term concern neg updat
potenti earn miss could drive share overshadow posit pipelin
current commerci busi whole current commerci busi
mainli us eylea sale ou eylea collabor revenu revenu
sanofi antibodi collabor project remain rel flat see
headwind eylea franchis growth antibodi collabor
pipelin prospect like regeneron pipelin note earli
assign concret valu asset could see upsid
indic expans dupix nasal polyp eosinophil esophag
revenu flow sanofi jv llimit impact
regeneron core could also see revenu upsid libtayo
beyond cutan squamou cell carcinoma cscc upsid like
limit profit share sanofi
 posit regeneron unlik engag transform
rel strong engin compani capac transact
estim would expect early-stag partnership similar
recent deal alnylam still compar gilead regeneron
acquir posit strength
neutral although like strength jakafi franchis think
pipelin whole remain rel immatur think opportun
itacitinib steroid-nav graft vs host diseas gvhd pemigatinib rare bile duct
cancer rel small compar current trajectori jakafi polycythemia
vera pv myelofibrosi mf could acquisit target
neutral posit jakafi product stream could attract pipelin remain
earli command major premium could also acquir earlier stage asset
current cash equival balanc
current commerci busi incyt current commerci busi project
grow late forecast us sale compound-annual-growth-rate driven
primarili jakafi mf pv lesser extent like approv
pipelin prospect like pipelin think whole asset data
remain rel immatur next year expect see launch
itacitinib steroid-refractori gvhd pemigatinib cholangiocarcinoma
rare bile duct cancer project pipelin asset
contribut addit sale
 posit think posit acquisit target
posit rel weak jakafi franchis would attract
acquir valu pipelin unlik fulli realiz
transact asset remain immatur main except incyt
licens topic ruxolitinib think could command premium
dermatolog immunolog focus compani could also see
acquir posit rel strength real pipelin hole
need fill compani strong cash equival balanc
could use acquir earlier-stag asset
biogen set-up remain challeng recent phase three failur aducanumab
alzheim diseas current commerci busi project declin
multipl sclerosi space becom crowd new oral medic launch
could see scenario gener gilenya aubagio avail new
patient would requir tri fail gener prior move brand therapi
end believ like upcom approv vumer enough
revers current cours beyond ms see competit threat sma franchis
novarti gene therapi zolgensma roche/ptc risdiplam
without aducanumab late-stag pipelin concern
enough high-impact/larg opportun asset help revers neg growth forecast
work al stroke pain unlik chang multipl revenu growth
trajectori think increasingli urgent need engag refil
pipelin revers current earnings/ revenu growth trajectori
current commerci busi current commerci busi like
declin next year compound-annual-growth-rate flat earn growth
driven share repurchas see headwind ms sma
franchis upsid biosimilar limit profit share jv
partner commerci europ
pipelin prospect follow failur aducanumab neg
pipelin think high impact/high potenti
asset help revers current cours project revenu declin
 posit remain acquir posit weak
simpli put need engag large-scal accret earn fill
pipelin current manag strategi priorit share repurchas could
help near-term earn noth help larger issu longer-
term growth could see multipl contract absent note
consid acquir share price remain depressedw
could see acquisit target
figur forward price-to-earnings larg cap biotech vs us pharma
credit suiss estim factset larg cap biotech celg note year exclud vertex due period net loss per share us
offer datecompani nameoff price rangeoff pricepricingrangegross proce market cap deal performanceperform inc pharma scienc scienc inc charl martineau univers toronto
start mega deal continu biopharma focu
mega merger bristol celgen valu deal pace beat
see figur put focu potenti compani could buyer
could acquir higher profil acquisit reinforc view key
therapeut area includ gene therapi roch buy spark buy
nightstar target oncolog lilli buy loxo usual
remain constant backdrop larg cap biotech usual buyer smid cap
seller think pipelin hole need growth main driver
key talk point remaind
valuat come high make small mid-cap name
attract view highlight valuat biotech come
significantli sinc high suggest small mid-cap target may
attract larger biopharma name figur still note hot area
name target oncolog gene therapi recent premium paid suggest
asset competit high demand
figur valuat come premium
dealstot deal valu take-out premium charl martineau univers toronto
look coverag univers divid name two main categori
buyer target assess whether posit rel strength
weak see vertex buyer strength capac
urgenc perspect gilead buyer weak
pipelin hole potenti near-term capac constraint figur overview
assess coverag len review company-specif
assess well detail analysi given
believ signific pipelin hole follow phase discontinu
regeneron pipelin revenu gener subject collabor profit share agreement increment end-us sale necessarili get book revenu regeneron
buyer strength amgen regeneron vertex
outperform rate regeneron vertex base assess
current busi intern pipelin potenti believ
compani need deal buy pipelin asset thu view buyer
capac strength purchas capac see
figur estim
assess exclud merger could financ stock factor current
cash debt capac announc share repurchas agreement
futur cash flow believ parti transact
size bristol/celgen rather smaller-scal purchas would help bolster
late-stag pipelin estim rang deal would
quickli accret ep re-rat share figur assess
deal capac initi screen compani think seattl
genet bluebird bio nektar array biopharma would attract candid
name compani oncolog focu
cs net potenti premiumneurocrinec net potenti premiumregeneronc pt pipelinenmnmd net potenti charl martineau univers toronto
regeneron capac acquir asset outright compani prefer ink
partnership either allow share sanofi teva access earlier-
stage assets/platform alnylam bluebird bio consist commentari
compani believ would acquir small mid-siz biotech
compani would merg larger compani alnylam deal partnership
regeneron invest via alnylam stock purchas up-front
cash licens fee alnylam agreement cover develop ocular diseas
liver diseasewith variou split mileston royalti arrang
bluebird bio partnership smaller initi invest two compani
select six initi target share equal cost ind
asset pre-clin opt-in regeneron compani enter cost
profit-shar arrang think deal indic
busi develop regeneron engag go forward manag
interest buy near-term revenu
note much valu share novel drug develop
asset later-stag pipelin come regeneron effort still
appli framework believ regeneron capac
deal expand see figur
vertex stand gener cash flow next year combin
current net cash give compani signific dri powder deal
expect compani take debt financ transact highlight
signific capac could help financ transact see figur
assess vertex deal capac much current vertex thesi predic
continu growth expans cf franchis littl ascrib non-cf
pipelin believ vertex need deal revenu growth
best growth profil among cover larg cap name broader us biopharma
recent compani commentari suggest early-stag deal remain strategi
vertex like similar deal crispr establish prior
crispr ipo well collabor asset enter clinic
trial compani current focu earlier stage deal three categori cystic
fibrosi anyth could addit current treatment regiment technolog
tool address seriou diseas gene edit pipelin asset
transform seriou diseas specialti market
enter increas flexibl deal would
broaden pipelin enabl us continu explor seriou diseas
multipl modal technolog
also emphas
see us deal on-market late-stag product
essenti buy revenu growth next year simpli
need revenu growth cf go provid
vertex acquir expect small early-stag bolt-on style dealslik within
gene therapi space vs current partnership crispr focus genom
edit current primari focu compani develop tripl
combin continu progress reimburs agreement wwwe could see
movement small gene therapi compani
buyer weak gilead
under-perform neutral gilead given broader structur issu
respect busi follow failur aducanumab
signific pipelin gap help revenu growth compani point
earlier stage work think develop al psp remain challeng best
acquisit nightstar provid mid- late-stag gene
therapi asset think revenu potenti clinic asset small thu
point need anoth deal acceler growth less construct thesi
predic neg revenu growth outlook especi likelihood
competit asset sma approv think buyer
weak need transact becom increasingli urgent recent
announc share buy-back signal us manag concern
prop near-term stock price vs buy long-term growth
manag
busi warrant continu multipl compress absent
reinvest growth see figur error refer sourc found biogen deal
capac review propos transact later section
gilead assess neutral gilead hiv busi like continu
support revenu base near-term howev growth day hcv boom
think acquisit kite expens brought cell-therapi platform still
acquisit enough return revenu earn growth think gilead
need buy nearer-term growthespeci light failur selonsertib phase
trial like gilead pipelin gap fill intern
develop asset think gilead posit buyer weak given
urgent need transact quit dire gilead longer growth stori
among biopharma concern new ceo cut near-term expens
report layoff salesforc expand margin prop earningbut
properli invest sustain growth given oday histori roch expect
signific bd near-term note recent ink deal novo interest
use weight loss drug nash seem novel us still run
analysi gilead see dri powder see figur
less certain would strateg fit gilead asid nash focus
compani intercept vike madrig genfit need get better sens oday
strateg vision comfort make call gilead buy beyond
nash oncolog
 may increasingli import examin potenti
analysi may need help reacceler revenu earn
growth share may screen cheap rel large-cap biotech
major pharma stock think low multipl justifi owe current growth
profil view may one way improv multipl growth profil
believ acquisit nightstar like result signific
screen biotech compani market cap higher believ
busi size could use partner screen compani
could fit strateg neurolog rare diseas focu like
figur rank compani rate scale low strateg fit
help chang
growth
 unrel therapeut area high strateg fit relat therapeut area
potenti near-term ep accret small mid-cap space sarepta
neurocrin screen well basi base premium achiev complet
acquisit biotech space ytd believ premium
current share price/enterpris valu would ration among larger cap alexion
biomarin also screen well though due size deal structur would like
akin merger cash debt stock might involv outsid
market cap group therapeut also examin given competit
threat pose biogen sma franchis compani cover credit suiss
analyst analysi use estim neurocrin sarepta biomarin
alexion cover use factset consensu given biogen
acquisit histori expect execut major acquisit
near term howev think given manag statement capit avail
employ toward and/or buyback might consider
light aducanumab discontinu
compani cover cs analyst martin auster alexion op pt biomarin op pt sarepta therapeut op pt
earlier year biogen cfo discuss potenti capit transact share
repurchas use methodolog updat recent deal buyback
estim capac may either
issu share debt beyond compani discuss execut deal
furthermor compani recent indic interest
acquir earlier-stag asset failur aducanumab may mean may
consid later-stag asset figur estim deal capac
includ recent transact nightstar author
among small/mid-cap neurocrin sarepta therapeut
three compani approxim market cap assum
premium base analysi recent transact januari ytd
figur compani oper neurosci field
commercial-stag product promis pipelin could provid long-term
option neurocrin sarepta also gene therapi space
figur biotech transact valu premium
figur biotech transact valu premium
therapeuticsrec approv zulresso postpartum depress
consensu expect zulresso current expect
increas highlight potenti attract revenu opportun think
potenti combin could improv growth trajectori
revenu base also contribut earn growth howev assum
potenti purchas premium would requir debt financ transact ep impact
appear limit see figur refer sourc found assum
approxim assum cash new debt
equiti issu
conserv could acquir
assum equiti issuanc capac financ
transact cash hand debt issuanc assum would dilut
share purchas compani
highlight zulresso psychiatri space see adjunct biogen
core focu neurolog howev earli day zulresso launch
could hamper initi sale would meaning impact top line
near term addit drug administr difficult given mother
recent child must infus hospit set hour compani
later-stag pipelin asset develop includ major depress disord
insomnia parkinson diseas think acquisit small-molecul drug vs
broader platform would effici effect way fill pipelin
howev revenu upsid could help near term furthermor
headquart cambridg could eas integr two compani
figur illustr scenario analysi potenti combin
inputsusesacquirorbiibshar drop-down sagepurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu transaction- pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
note analysi perform non-gaap basi exclud amort deal relat intang
neurocrin biosciencescommercial-stag compani asset broad
neurology-focus pipelin full assess neurocrin see initi
coverag high-level think revenu upsid ingrezza tardiv dyskinesia
royalti orilissa endometriosi like uterin fibroid could meaning
contributor sale estim neurocrin revenu
pro-forma basi estim could increas five-year compound-annual-growth-rate
top line includ impact interest expens
complet deal estim ep could increas impli
increas versu alon see figur refer sourc found
assum purchas premium conserv could acquir
neurocrin approxim assum cash new debt
equiti issu
asid ingrezza orilissa neurocrin rich pipelin core
outperform rate includ congenit adren hyperplasia gene therapi
partnership voyag develop treatment parkinson diseas
pd friedreich ataxia believ complementari current
neurolog focu especi rare diseas neurodegen diseas believ
gene therapi program pd could complementari current
view combin neurocrin could fit compani
would acquir two current revenu stream strong neurology-focus pipelin
howev ingrezza orilissa remain earli stage launch may
meaning chang near-term revenu trajectori neurocrin locat
san diego make integr challeng
figur illustr scenario analysi potenti neurocrine-biogen combin
note analysi perform non-gaap basi exclud amort deal relat intang
sareptacommercial-stag compani therapeut
treat duchenn
therapi platform could gener sale accord small mid-cap
team assum drug ultim approv estim could
chang revenu outlook small mid cap team estim
potenti revenu sale increas improv top line
year compound-annual-growth-rate includ impact interest
expens complet deal estim ep could increas
see figur refer sourc found estim biogen
could acquir sarepta use combin cash hand new debt
equiti issuanc
sarepta offer extens platform duchenn muscular dystrophi therapi exon-
skip gene therapi compani also develop program charcot-
marie-tooth diseas mucopolysaccharidosi iiia limb-girdl muscular dystrophi
asset would fit neurolog rare diseas focu locat
headquart cambridg would allow eas integr
inputsusesacquirorbiibshar drop-down nbixpurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu transaction- pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
figur illustr scenario analysi potenti sarepta-biogen combin
note analysi perform non-gaap basi exclud amort deal relat intang
inputsusesacquirorbiibshar drop-down srptpurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
larger scale biomarin alexion
explor two larger compani also screen well strateg sens view
larger size compani deal
compani would like requir issuanc stock addit cash/debt
biomarinmultiproduct orphan compani gene
hemophilia smaller compani alexion also see
possibl could acquir biomarin structur mix cash
addit debt stock biomarin solid revenu base rare diseas mainli
focus enzym replac therapi ert would rel synergist
biogen sma franchis greatest upsid potenti would biomarin gene
therapi program valrox hemophilia small mid-cap biotech team estim
peak sale could drug biomarin current revenu base
auster model expect grow assum contribut
vosoritid hemophilia gene therapi could alter revenu
trajectori given current consensu revenu expect would see
combin biomarin potenti increas revenu
oper incom five-year compound-annual-growth-rate could possibl increas
factor potenti share dilut cost synergi interest expens estim
pro forma ep would
see figur refer sourc found note
oper incom may increas would signific dilut share issuanc
requir estim could acquir biomarin
structur mix cash debt share
slightli small/midcap biotech team acquisit price
biomarin offer access late-stag gene therapi see deal
like compani divest hemophilia made strateg
move away hemophilia see get back space follow
spin-off bioverativ biomarin locat san francisco bay area
would harder integr may limit cost synergi given sg
expens requir market sell ert around world rare diseas
figur illustr scenario analysi potenti biomarin-biogen combin
note analysi perform non-gaap basi exclud amort deal relat intang
inputsusesacquirorbiibshar drop-down bmrnpurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
alexionorphan diseas compani solid revenu base among compani
screen alexion largest market cap larg size
potenti combin alexion would akin merger assum
would requir use cash debt stock issuanc
combin alexion would larger gilead
alexion solid revenu base soliri ultomiri strensiq kanuma
small/mid-cap biotech team estim revenu increas
could chang growth trajectori revenu base
alexion beyond current compani stand-alon
alexion complet focus neurolog gmg indic soliri
also develop asset neuromyel optica spectrum disord nmosd
wilson diseas wilson therapeut acquisit april also neurolog
upsid potenti transact size lie potenti strengthen
revenu base compani realiz cost synergi could help improv
long-term earn margin see figur refer sourc found
alexion locat boston area would make eas
integr believ may challeng alexion still locat
new alexion current cfo paul clanci
indic know busi could navig alexion legaci
busi risk execut believ potenti
bring valu sharehold especi post-aducanumab environ
figur illustr scenario analysi potenti alexion-biogen combin
note analysi perform non-gaap basi exclud amort deal relat intang
inputsusesacquirorbiibshar drop-down alxnpurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
therapeut candid screen market cap
small meet initi criteria howev look criteria
defens posit potenti earn accret screen well pro
forma analysi use consensu estim see accret assum
combin financ use cash hand howev potenti gain
revenu oper incom may enough improv growth profil
avoid need futur asset see figur refer sourc found error
refer sourc found
figur illustr scenario analysi potenti therapeutics-biogen combin
note analysi perform non-gaap basi exclud amort deal relat intang
major pharma large-cap biotech gilead vertex regeneron
would unlik acquir given weaker pipelin declin
commerci busi believ major pharma large-cap biotech would
interest combin ms busi remain stabl cash
gener sma still provid revenu opportun believ less appetit
deal scale bristol celgen even revlimid celgen broader
late-stag pipelin like accret bristol colleagu vamil divan
work deal first-look follow-up deeper look wellington opposit holt
analysi howev possibl becom attract takeout
candid could increas share remain depress declin
inputsusesacquirorbiibshar drop-down ptctpurchas price share cap purchas target target debt acquisit share rate new share combin incom ww total ww total combin ww total oper incom oper oper combin oper incom interest deal-rel debt combin profit tax combin net weight average share calcul new share issu transaction- pf combin weight average dilut stand-alone dilut combin dilut accret accret charl martineau univers toronto
innov despit departur gottlieb
product
fda remain integr compon biotechnolog sector recent show
flexibl approach drug develop maintain highest
standard feder agenc respons approv new drug also
work manufactur help develop drug design clinic trial fda also
respons approv gener biosimilar signific impact
coverag univers broader biopharmaceut sector past year
seen uptick fda product drug approv rel
higher rate estim nda bla approv rate nearli
see figur think show agenc work industri
partner feel standard clinic trial diminish rather
fda industri better align earlier drug develop process determin
drug trial need demonstr efficaci safeti perspect
approv see releas variou guidanc document inform industri
develop seek approv varieti drug mani new
emerg area nash gene therapi even eosinophil esophag note
fda also begun show flexibl trial allow call
acceler approv basi surrog endpoint biomark
shown correl diseas progress improv coverag
think fda done good job balanc need robustli show safeti efficaci
potenti therapeut allow flexibl effici bring medicin
commission gottlieb fda commission seen partner
industri maintain highest standard drug develop public
health departur earli april disappoint mani biotechnolog
industri action commission view brought agenc
forward benefit stakeholdersinclud industri public among mani
accomplish implement centuri cure act establish fda
oncolog center excel use real world digit inform highlight
danger vape think open wide-spread use twitter engag
public reflect posit chang within agenc leadership
fda approv cell-bas therapi cancer novarti kymriah gilead yescarta
gene therapi spark luxturna even biosimilar
commission believ disruptor biopharma come year
agre gottlieb asset fda
ned sharpless name act commission industri hope follow
gottlieb lead drive effici innov open fda think
experi director nation cancer institut familiar
biotechnolog industri co-found two earli stage biotechnolog compani
like seen posit industri within nih discuss partnership
fda first week job activ twitteron gottlieb favorit
way commun public optimist continu
priorit public health also continu push innov biotechnolog sector
given know sharpless optimist remain
posit factor sectorensur highest level efficaci safeti
flexibl effici develop novel therapeut
drug pricingth overhang like
remain elect
drug price rhetor capitol hill like intensifi head
elect given control senat hous white hous see limit
progress topic near-term anyth could see action hh
depart human servic led secretari azar rebat part
plan could also see reimburs medicar part office/hospit
administ drug shift reimburs part manag privat
insur compani prescript drug coverag examin spend data
part also identifi compani could impact
chang way reimburs medicar handl note speak
polici expert assess current polit situat think
anyth pbm pharmaci benefit manag also known middl men
pharmaceut suppli chain stand lose rebat elimin longer-
term regardless win believ compani end
less reliant price increas drive revenu growth
risk part b- current commerci busi regeneron
risk part d- current commerci busi gilead
reimburs part base intern price risk
medicar advantag part part drug price rule finalizedminim
impact coverag may releas final rule medicar advantag
part price main updat prohibit gag claus pbm prohibit
pharmaci disclos drug cost lower insur use
implement signific chang protect class hiv therapi could
limit choic patient allow plan use step-therapi util manag
current polici allow part provid use step therapi five six protect class
antiretrovir hiv medic exclud final regul would allow
part plan medicar advantag use step-therapi new medic start
scenario could potenti see impact regeneron eylea plan requir
use off-label avastin note rule final would appli
medicar advantag plan tradit medicar part
overal main object rule increas transpar without substanti
chang rebat price see increas cost sensit part
major chang overal program importantli rule includ refer
price shift part part also think discuss drug cost
provid level could help inform choic name use gener vs brand
see major impact cover compani
discuss long-term polici possibl medicar part beyond
discuss shift medicar part reimburs part on-going sinc
obama administr obama-era demonstr project hh
formal cancel call current administr essenti reviv
effort current polici provid doctors/priv practic hospit
reimburs drug administ office/ hospit set asp
averag sale price plu mark-up januari mark-up reduc
sequestr cut critic note system incent physician
choos lower cost altern actual drive usag expens
product mark-up base cost drug medicar specif
prohibit negoti directli manufactur must accept averag sale
price basi reimburs
idea part reform price reform idea tri
remov econom incent use higher-pr therapeut reduc percent
mark-up appli addit reimburs tie drug cost
recent propos current administr tie reimburs part drug
index intern price hh propos link octob accord hh privat
vendor procur part drug would procur drug distribut physician
hospit take respons bill medicar vendor would aggreg
purchas seek volume-bas discount compet provid busi therebi
creat competit none exist today physician would receiv addit
payment tie current mark-up rather set payment store
handl product
propos yet implement skeptic industri novemb
ceo regeneron indic
think govern secretari laid gauntlet said
listen like -- administr like american pay higher
price drug compar european skate back tend agre
think come solut think import lower
price answer rather see us export higher price
figur whether equilibrium reach
could also see shift reimburs current part protocol one
close resembl part scenario privat insur compani would
negoti directli manufactur use rebat tier therapeut administ
office/hospit set part current cover prescript drug
administ office/hospit set shift would elimin asp method
reimburs replac someth akin see
commerci insur market could allow negoti drug
reimburs part would still issu rebat address next
section
regeneron eylea risk tradit part reimburs chang
help quantifi company-specif impact shift part reimburs look
spend data part drug up-to-d data look
top drug account total medicar part spend
identifi product sold compani coverag see compani
could impact sort reform take place regeneron eylea remain
highest spend rituxan second highest spend
exposur rituxan revenu genentech/roch jv
note novemb biosimilar rituxan approv mean
sale expect rituxan contribut alreadi declin
thu neg price pressur propos would depress estim
also could mean shift part happen could see roch use
contract higher rebat push brand rituxan ahead biosimilar could
slightli posit altern could see payer prefer use
biosimilar ahead brand rituxan depress sale estim even
product could impact amgen neulasta epogen aranesp
alreadi declin due biosimilar competit pressur amgen prolia
forecast declin like neulasta epogen aranesp biogen tysabri
forecast declin launch ocrevu figur overview part
drug risk due potenti reform
figur medicar part spend drug top
us depart human servic
rebat reform part potenti company-specif impact second key piec
polici discuss remov safe-harbor allow pbm accept rebat
manufactur current pbm part commerci plan accept
rebat discount manufactur list price drug secur better
formulari placement enhanc access arrang pbm could welcom
list price increas rebat would also increas thu allow keep
increasingli larger portion differ price gross net
rel basi gross-to-net gap shrunk recent figur valu total
differ gross-to-net increas figur differ price
pbm gener profit hh remov safe harbor rebat make
would compet list price vs opaqu rebat remain trade secret
accord mani pbm rebat would allow plan beneficiari see
januari propos rebat reform think rebat reform could
eventu happen note rule includ safe-harbor
medicar part spend data highlight at-risk product gilead
product compani coverag risk
regeneron eylea part could see revenu disrupt rebat
elimin gilead hcv product harvoni epclusa subject high
discount rebat remov rebat would necessarili impact gilead given
current avail author gener harvoni price averag net
cost gilead might compet hcv medic would need
see real reduct cost bring mavyret list price significantli tecfidera
benefit pbm rebat given competit ms market would
cut list price remain competitiveespeci potenti generic
gilenya launch novel oral product revenu enbrel forecast
declin come year rebat key vehicl secur formulari access
product crowd ra/ anti-tnf space think rebat remov
aggress compet list price could lose access
place even revenu risk hand sensipar like face gener
competit near-term fda alreadi approv gener yet litig prevent
launch expect sensipar revenu declin near-term thu impact
rebat reform part drug would like meaning figur
assess top drug medicar part spend
previou yearlist pricenet gross-to-net reduct brand name drugstot valu chang previou charl martineau univers toronto
figur medicar part spend drug top
us depart human servic
polici maker target manufactur pbm parti
respons rise drug price assess think manufactur
respons list price increas rebat discount pbm also
contribut rise cost pbm financi motiv increas amount
rebat portion amount get pass plan payer
govern employ increas take side situat rather
point pbm captur profit everi flow
us retail drug distribut system privat insur figur
hypothet exampl paper sood et al link insur also captur
profit system pbm insur profit could go
per spend pbm/insur higher list price increas rebat
potenti clear profit driver pbm
figur hypothet us retail drug distribut system
assess drug price debat elect
rhetor like intensifi especi democrat parti front runner
becom clear
current balanc power like limit legisl polici chang
believ democrat gop come togeth pass sort
impact drug price reform
think someth could done reimburs part
believ index reimburs intern basket current
propos implement shift reimburs part d-
type system could happen well elimin protect class
could see elimin rebat safe harbor part potenti
expans commerci plan would requir legisl could
done secretari
quantifi potenti impact across coverag therapeut cover
medicar part part figur
figur part reform- compani risk
figur part reform- compani risk
suppli chaincaptur usescaptur net revenuecompani drug spend totaltotalat revenuecompani drug spend totaltotalat charl martineau univers toronto
area watch across
coverag broader sector
launch coverag identifi five key area watch next
year includ allergy/immunolog oncolog target therapi genom
manipul gene therapi edit migrain therapi address
diseas central nervou system cross-compani assess
view compani pipelin rel peer five area repres import area
develop compani coverag broader biotechnolog sector
overal think area remain challeng other see innov
area near-term review key asset develop project watch
compani specif detail found recent company-specif initi
figur cross-compani analysi pipelin coverag compani
regeneron pipelin revenu gener subject collabor profit share agreement increment end-us sale necessarili get book revenu regeneron
pt pipelin lead biosimilar oncolog migrain tbd allergy/ total cs pt pipelin lead multipl sclerosi tbd gene therapi lag total pt pipelin lead infecti diseas lag nash total pt pipelin lead cystic fibrosi tbd gene therapi pain total pt pipelin lead oncolog tbd total pt pipelin lead neurosci tbd gene total lead allergy/immunolog tbd ww end-us sale dupix libtayo pt pipelin lead peanut charl martineau univers toronto
allergi immunolog
market remain immatur ad asthma point addit
upsid regeneron dupix also highlight promis
effort across allergi immunolog
lag none coverag
look overal autoimmune/ inflammatory/ atop market see continu
growth market expans potenti novel treatment ad asthma
consist project growth believ regeneron dupix like
remain leader ad like asthma space well think
continu expans indic penetr address popul
larg market still rel immatur see figur dupix like
enjoy continu growth despit potenti competit ad asthma
figur estim autoimmune/ inflammatory/ atop market
footnot estim total sale per indic evaluatepharma cs project base us brand price assum peak treatabl popul biologics/novel agent
us ra psoriasi ulcer coliti crohn atop dermat asthma
ra moder -sever psoriasi moder -sever ulcer coliti moder -sever crohn moder -sever atop dermat moder -sever asthma ww market us moderate/sever maturityapprov agent per target tnf-alpha clinic per target btk receptor receptor charl martineau univers toronto
competit ad come novel biolog jak expect
competit novel system space ad think dupix first-mov
posit continu help drive usag still close watch emerg
competit asset target novel select jak inhibitor ad
interest develop etokimab dermira lebrikizumab
upadacitinib figur overview novel therapeut
develop ad speak physician seem still unmet need
patient success treat dupix gener neg
use jak inhibitor upadacitinib baricitinib given potenti lab
monitor increas risk cv event deep venou thrombosi pulmonari
embol think daili oral medicin guarante advantag
subcutan inject overal think dupix well posit
well long-term ad still room multipl product note
dupix first-to-market posit help solidifi like domin posit
figur novel therapi treat atop dermat
asthma crowd market howev prior approv dupix
efficaci system biolog seen mediocr inde proprietari
physician survey suggest dupix compel efficaci safeti
data figur physician project prescrib dupix vs
novel asthma drug includ xolair next month highlight
survey also indic excit around amgen/astrazeneca tezepelumab
target tslp thymic stromal lymphopoietin cytokin upstream
indic might efficaci type asthma patient usual
stratifi eosinophil phenotyp phase data promis
figur howev could increas risk infect assess
asthma market see dupix sale asthma eclips
figur compel therapi review
therapeut target dose efficaci data
figur compel therapi review
safeti advers event data
respond
respond
figur efficaci comparison across novel asthma therapeut approv investig
producttargetsroadosingselect trialsreduct exacerbations/yearoth considerationstri vs pbo week trial vs pbo week trial eosinophil vs pbo reductiontri eosinophil vs pbo reductiontri vs pbo reductiontri eosinophil vs pbo reductiontri blood eosinophil vs pbo reductiontri blood eosinophil vs pbo septemb add-on therapi patient eosinophil phenotyp ongoingpivot trial demonstr reduct overal popul reduct high eosinophil popul reduct among differ dose cohort similar result observ patient regardless blood eosinophil count enrollmentnucala mepolizumab approv administ healthcar profession monitor patient administr biolog agent recommendedfasenra benralizumab approv administ hc profession monitor patient administr biolog agent recommendedxolair omalizumab approv box risk anaphylaxi administ hc set prepar manag anaphylaxi observ patient appropri period time administr cinqair reslizumab approv box risk anaphylaxi administ hc set healthcar profession prepar manag anaphylaxi teva announc failur sc formul ciqair charl martineau univers toronto
beyond immunomodulatori allerg diseas believ
continu interest potenti approv aimmun peanut allergi
therapi aim desensit patient peanut allergi recent bla
accept fda expect advisori committe meet second-half
year approv like earli like first fda approv therapi
peanut allergi aimmun competitor dbv face competit setback
decemb voluntari withdraw bla applic compani
expect refil behind aimmun like launch
believ poorer efficaci profil
continu innov target therapi pois address difficult
treat tumor type extend life reduc burden cancer
initi highlight work regeneron gilead lesser extent
develop novel oncolog therapeut aggreg level ww oncolog market
across indic therapeut expect grow compound-annual-growth-rate
see figur much growth driven merck
bristol growth driver expect see increas use like
approv novel target therapi yescarta kymriah novel bispecif even
novel small molecul drug like setup oncolog pipelin novel
bispecif bite design treat believ high valu target bcma
multipl myeloma note regeneron also expand oncolog recent
approv libtayo cutan small cell carcinoma
gilead perspect character cell therapi franchis nice-to-hav
platform believ sale yescarta move needl near-term
agre kite acquisit given gilead access novel therapeut
modal need see clinic data fulli justifi purchas price recent
write-down anti-bcma asset boost confid view incyt
oncolog pipelin outsid mf pv still recov failur
epacadostat i/o melanoma think pemigatinib fgfr inhibitor could
interest asset compet jnj erdafitinib novarti right
inhibitor compani expect file nda
also less interest us given crowd i/o field
lack success inhibitor
agre oncolog franchis continu grow novel target therapi
develop approv howev oncology-play result outsiz
perform think investor need select choos target
therapi invest regeneron favorit
broad oncolog pipelin could produc viabl therapeut could
address high-valu target formal model investig
oncolog asset believ investor focu develop across
pipelin figur next year success asset potenti
drive share upsid could meaning contribut evolut
commerci busi success one two bispecif brand
bitesbispecif t-cell engag could easili gener increment sale per
asset like approach address hematolog malign
platform compani coverag take car-t approach clinic
success bite could less costli faster option address diseas
multipl myeloma mm acut myeloid leukemia aml given myriad constrain
autolog car-t therapi seen anem sale kymriah yescarta
believ opportun bi-specif heme-onc beyond bite
also pursu cell therapi small molecul hematolog malign
emphas either-or situat
car-t remain competit field three main player dlbcl space
target asid novarti gilead also compet
bristol/celgen assum approv per cvr
structur bristol/celgen deal across therapi data look rel compar
note orr overal respons rate month slightli higher
vs yescarta albeit yescarta patient trial
note patient treat kymriah orr
patient month follow discontinu earlier evalu
efficaci think long-term real world data essenti determin
winner dlbcl car-t space also highlight abil administ
outpati set could alter usag curv one limit factor uptak
facil constrain notic higher proport patient treat
outpati set kymriah lesser extent patient
treat outpati set yescarta
think could edg safeti potenti neg
pressur yescarta usag note seem lower rate
cytokine-releas syndrom common side effect treatment patient
immun system goe drive releas larg amount cytokin
blood lower rate potenti indic safeti therapi less associ
risk death neurotox nt also key concern higher rate seen yescarta
kymriah patient highlight far fewer patient experienc nt
patient vs yescarta kymriah figur summar rel
efficaci safeti across three main target car-t therapi
figur car-t efficaci safeti comparison data
progress diseas remain challeng especi follow
discontinu phase trial aducanumab
think remain signific opportun across diseas note
compani must robust clinic develop program support valuat
across indic ms pain evalu pharma estim ww market
therapeut could reach see figur
number point continu growth invest across biopharma
coverag think neurocrin best setup success growth
anchor strong launch ingrezza tardiv dyskinesia see figur
recent posit phase data asset also point recent ink
deal voyag therapeut develop gene therapi treat parkinson diseas
friedrich ataxia set remain challeng follow late-stag failur
aducanumab alzheim limit confid success asset
approv could multipl changer
absent revenu program remain concern long-term growth
profil especi project contract ms busi
revenu driver neurocrin ingrezza td follow approv april
ingrezza treatment tardiv dyskinesia td key revenu long-term
valu driver neurocrin ingrezza vesicular monoamin transport
inhibitor approv link pi use treat movement disord tdwhich side-
effect prolong use antipsychot use bipolar schizophrenia
depress teva austedo also inhibitor also approv treat td
although dose regimen black box warn limit use indic
much upsid share root upsid growth ingrezza notabl
compani achiev net product sale nearli total
prescript believ consensu expect reason inde
beatabl histor sale consensu figur given superior profil drug
high unmet need td rel low penetr td market see figur
estim vs consensu
believ ingrezza reach peak sale despit strong launch
base discuss physician market research believ
addit upsid remain base
ingrezza best-in-class treatment td due chiefli conveni dose per
discuss neurologist psychiatrist
continu commerci invest neurocrin maxim penetr
neurocrin foray gene therapi recent sign collabor agreement
voyag therapeut januari neurocrin voyag enter
collabor agreement develop gene therapi potenti treat pd
friedreich ataxia fa neurocrin paid voyag up-front cash
equiti invest access vy-aadc pd fa think
anoth smart busi develop invest diversifi pipelin still
stay core neurolog focu seen littl data specif gene
therapi product asid phase trial publish annal
neurolog link deal repres lower-risk entri point gene therapi
program expect next key data point includ updat enrol
phase clinic trial pd first patient decemb updat
inform candid select program fa
multipl sclerosi like remain core compon commerci
base busi near-term inde look whole less
concern perform ms franchis vs lack impact pipelin
upsid believ ms growth driver forecast
contract next year also note like well appreci
investor street forecast world-wide ms franchis revenu compound-annual-growth-rate
vs consensu see figur ms franchis estim vs
consensu time expect continu crowd marketbolst novel
asset oral novarti mayzent celgen ozanimod iv roch
ocrevu space still think continu abl compet
potenti approv vumer diroximel fumar could provid better
toler profil vs tecfidera despit continu crowd number ms patient
continu increas could benefit
bolster view ms market conduct physician survey better
understand trend usag futur habit overal three key takeaway survey
physician satisfact ocrevu high increasingli attract
option despit histor ocrevu usag treatment-nav set low
larger increas expect treatment-experienc oral therapi unlik
see signific eros ocrevu primarili take share tysabri
inject includ detail ms survey initi
like remain leader sma even emerg competit
near-term expect nois like fda approv launch novarti
gene therapi zolgensma sma impact share long-term continu
see durabl franchis note like remain leader
sma despit emerg competit gene therapi roche/ptc oral splice
modul worst case scenario could see newli diagnos type patient
treat zolgensma prior symptom would sever dampen new type
patient start spinraza think drastic shift unlik immedi
even newborn sma type treat zolgensma see coupl
hundr million dollar impact project peak sale note
patient like get treat spinraza linethu total
destroy revenu base clinician think might synergist
effect treat patient zolgensma spinraza could see
combin use zolgensma gene therapi target gene
payers/govern would support two high-pric therapi sma patient
potenti provid addit effect
gene
base sma model spinraza account signific competit
risdiplam zolgensma across geographi assess biogen sma
busi discount spinraza benefit first-mov advantag
compel clinic trial real-world evid also realiz competit
product near-term horizon view zolgensma could provid
compel altern newli diagnos patient assum increas newborn
screen non-inferior efficacy/safeti furthermor zolgensma could provid better
long-term valu vs spinraza depend potenti list price durabl singl
treatment vs chronic see competit risdiplam conveni oral
dose potenti competit price note risdiplam small-
molecul oral administ splice modul could easier administ
need intrathec inject also like less costli manufactur orphan
drug price function address patient valu society/th health care
system cost manufactur sometim factor could see risdiplam undercut
price spinraza help drive usag
base case base current assumpt lose major
share newli diagnos market zolgensma model
assum patient diagnos newborn screen type
time diagnosi month therefor time proport type
patient would increas assum patient better candid
gene therapi model zolgensma captur exist
preval patient market also assum competit risdiplam begin
 gain preval market share follow
launch sma classif scenario see peak
ww sale declin figur detail
bear case assum zolgensma captur signific share
sma new incid popul preval opportun
base case model zolgensma launch year
europ japan come on-lin significantli reduc incid
popul treat spinraza key differ base
bear scenario assum risdiplam take major share
remain preval opportun view oral therapi differenti
better altern chronic intrathec inject assum efficacy/safeti
non-inferior result peak sale similar
base case see sale less base case
figur detail
figur bear case risdiplam take major share preval opportun
bull case assum zolgensma captur signific share
sma new incid popul preval opportun
base case key differ base bull case
assum risdiplam approv spinraza abl maintain share
preval market key market result peak sale
higher peak sale base case figur
detail
figur bull case spinraza viabl option
see larg gap within pipelin compani later-
stage asset noth nearli excit stock move aducanumab
later stage asset focus vixotrigin trigemin neuralgia
move phase glibenclamid lhi stroke current phase recent
acquir asset nightstar transact nsr-
rpgr view none program significantli move needl
term revenu growth earn growth multipl expans think earlier work
amyotroph later sclerosi al progress supranuclear palsi psp
parkinson diseas interestingbut earli us assign meaning
valu focu analysi lack excit pipelin core neutral
thesi sharesw see pipelin drive meaning
renew focu recent launch cgrp consensu expect
aimovig botox remain leader
lag none coverag
migrain part broader market includ separ subsect
given recent launch cgrp continu innov space believ
grow therapeut area assess marker think novel
migrain like get crowd three approv system therapi includ
novarti aimovig near-term approv oral anti-cgrp medic
allergan utogep biohaven rimegep watch
commerci uptakea consensu continu peg migrain market grow
compound-annual-growth-rate figur consensu
expect migrain market despit crowd commerci
landscap still view leader migrain space launch
aimovigth first anti-cgrp antibodi approv fda
first-to-market advantag increas competit pose signific headwind
aimovig first fda approv may calcitonin gene-rel peptid cgrp
inhibitor stiff competit ajovi teva emgal lilli like captur
market share product launch phase approv
septemb first market bump aimovig saw total prescript
ajovi emgal compar launch pace
see stronger nrx figur figur post launch aimovig vs ajovi
emgalityhighlight durabl head-start note aimovig
stronger launch start see consist declin nrx
complic market expect addit competit injectable/iv market
alder eptinezumab furthermor oral formul allergan biohaven
develop could increas competit see migrain market
get competit new market entrant rel undifferenti
data approv cgrp inhibitor brand prefer like determin
combin payer dynam dose conveni better side effect profil even
strong initi launch see aimovig lose market share competitorsstil
think consensu could account crowd market inde
slightli ahead consensu expect believ aimovig posit first-to-
market last impact penetr rel competitor
still despit headwind believ aimovig continu
domin player near term could import driver
compani revenu note benefit includ widespread payer coverag
load dose lower inject site reaction could help secur long-term
market leader slower growth vs competitor project revenu
us sale less royalti novarti royalti receiv novarti eu sale
deriv end-us sale us ou figur
compound-annual-growth-rate gener in-lin consensu note consensu
expect forecast stronger growth emgal compound-annual-growth-rate ajovi
compound-annual-growth-rate aimovig enjoy first market benefit give compani head
start negoti better payer formulari coverag discuss later detail
agre consensu emgal aimovig two main near-term player
space ajovi like come third mainli due less payer coverag overal market
share drug expect decreas new entrant oral dose becom
avail account market model
figur project revenu cgrp inhibitor cs vs consensu
gain clear competit edg cgrp difficult multipl player
aimovig continu face market eros emgal ajovi fourth player
alder eptinezumab current review fda pdufa
eptinezumab show slight advantag chronic set discuss later howev
uncertain would make commerci differ eptinezumab potenti fourth
market difficult erod progress made approv cgrp
nevertheless potenti room addit player alder could gain
oral cgrp migrain prophylaxi chronic set could also competit
threat sever year away ad competit mix oral therapi could
enter market earli allergan ubrogep current fda
review pdufa date biohaven plan file nda rimegep
zydi oral dissolv tablet rimegep grant prioriti review
fda therebi set potenti approv end howev drug
seek approv acut set near-term oral drug would like
smaller effect inject market chronic migrain oral drug
studi chronic migrain unknown efficaci drug would chronic
migrain prevent although third gener oral cgrp chronic episod
migrain prevent develop atogep allergan phase studi
prevent set episod migrain also highlight definit
sever episod migrain chronic migrain vari similar
margin headach day seem boundari two distinct
payer coverag potenti biggest factor brand adopt aimovig
emgal greatest coverag emgal widest coverag three
approv cgrp inhibitor list prefer formulari express script
optumrx figur aimovig prefer express script optumrx
exclud ajovi least cover drug prefer non-
prefer express script optumrx prefer coverag like driven
price discount payer recent reuter articl link articl suggest teva
less will discount ajovi contract discuss confidenti
think lilli like will give larger discount rebat
payer still teva state earn compani happi current
coverag commerci sector contract vari year year think
unlik see signific chang coverag landscap near
term factor play could help aimovig emgal get wider
coverag strong us presenc relationship payer addit aimovig
initi advantag first market month could see payer
dynam chang market becom competit drug maker like
increas discount gain maintain coverag
figur formulari coverag fda approv migrain therapi
efficaci chang
clinic data rel undifferenti among inject therapi clear winner
trial data alon clinic data figur highlight pivot trial three
approv cgrp inhibitor eptinezumab fda review episod em
chronic migrain cm look
migrain headach
days/month obviou differ four drug emgal appear
perform better vs placebo em dose days/month reduct
similarli aimovig show similar efficaci em highest dose days/month
eptinezumab aimovig look good higher dose cm group number
differ drug note head-to-head trial data exist
therefor draw definit comparison drug essenti efficaci
side effect appear rel similar channel check physician
confirm current agent perceiv similar differ ajovi
eptinezumab approv less frequent dose could provid greater
pbmprefer formularynon-pref formularyexclusioncov live pbmexpress script aimovig amgn/nv emgal ajovi million caremark ajovi teva emgal -aimovig millionoptumrx unitedcar aimovig amgn/nv emgal ajovi charl martineau univers toronto
figur trial data inject cgrp inhibitor
product detail could play smaller role brand adopt aimovig load dose
better deliveri system lowest inject site reaction conveni comfort
may factor brand prefer prefer drug formulari
aimovig emgal conveni deliveri system autoinjector/pre-
fill pen compar ajovi pre-fil autoinjector shown improv
complianc success self-administr stauffer et al addit ajovi
syring suggest reason higher inject site reaction
vs aimovig emgal initi load dose first month emgal
small possibl signific disadvantag aimovig
aimovig erenumab emgal galcanezumab ajovi fremanezumab eptinezumabmechanismcgrp receptor inhibitorcgrp ligand inhibitorcgrp ligand inhibitorcgrp ligand inhibitorcompanyamgen/novartislillytevaalderindicationsfrequ em cm preventionem cm prevent cluster ha preventionhigh frequenc em cm preventionem cm preventioncurr statusapprov em cm approv em cm sbla cluster ha approv em cm bla em cm pdufa chang migrain headach days/monthem aris mg strive mg em em promis mg cm cm promis toler constip fatigu influenza nasopharyng nausea back paininjection-sit pain abdomin pain upper respiratori tract infectionsinjection-sit pain dizzi fatigueupp respiratori tract infect urinari tract infect fatiguedeliveri profilemonthli scmonthli scquarterli monthli scquarterli charl martineau univers toronto
genom manipul gene therapi gene
recent acquisit approv gene therapi brought
scienc experi lab patient commerci
leader none coverag
recent high-profil deal even approv genom manipul
space includ therapeut area one watch come
year consid cover compani leader space
note three program could provid pipelin upsid next
year recent acquir nightstar therapeut gain access mid-clin
stage retin diseas asset section discuss emerg
competit biogen spinraza novarti gene therapi zolgensma highlight
potenti disrupt natur gene therapi product discuss
could benefit acquisit sareptawith gene therapi platform
treat sickle-cel anemia beta-
note vertex collabor crispr develop ex-
hemoglobinopathi potenti applic cystic fibrosi neurocrin sign
deal voyag develop treatment parkinson diseas
friedreich ataxia think earli make call regard success genom
manipul project posit vertex approach still think
invest continu space move even person
target medicin gene therapi sale spark/ roch luxturna
project unadjust expect signific progress therapeut
sinc begin seen major transact
gene therapi space largest transact includ novarti
acquir avexi roch acquir spark
given consensu estim revenu growth gene therapi product think
two transact begin larg deal space see figur
overview key transact jan think genom
manipul akin biologics/ mab seen begin
larger transform biotechnolog next year expect continu
invest could see even clinic data across indic applic
note gene therapi deliv viral vector advanc vs genom edit
 crispr/ still think modal could attract larg
biotech pharma
vertex partnership crispr therapeut develop program
sickl cell diseas beta thalassemia
vertex enter collabor agreement crispr crsp
rate develop ex-vivo gene therapi treat sickl cell diseas
approach cystic fibrosi vertex paid crispr cash
provid addit convert loan proce
main program crispr partnership develop ex-
vivo gene therapi treat hemoglobinopathiesinclud beta-thalassemia sickl cell
diseas technolog use gene edit techniqu upregul
express gamma globin protein hemoglobin subunit commonli
present newborn infant symptom sickl cell beta-thalassemia
present infant typic high level fetal hemoglobin aim edit
genom patient hematopoiet stem cell upregul express
gamma globin protein give rise red blood cell contain hbf could
reduc symptom associ diseas remov
enhanc thought increas fetal hemoglobin
februari vertex announc first patient infus
phase clinic trial beta thalassemia clinicaltri gov link
compani specif see initi clinic data note
primari endpoint month post endpoint measur transfus reduct
least month think might stretch see clinic data
orlando fl would around month mark infus
might realist venu first patient enrol phase trial
sickl cell diseas februari infus expect healthi
donor saw increas hbf hematopoiet stem cell treat
acquirertargetd valuepremium lead asset/ hemophilia aluxturna hemophilia agili aromat l-amino acid decarboxylas aadc choroideremiansr-rpgr x-link retin neurolog lysosom storag myonexu girdl muscular charl martineau univers toronto
note applic earli therapi
recent enter clinic crispr market cap
assign formal valu program dcf valuat vertex share
edit new could see competit sickl cell/ beta
thalassemia space highlight recent advanc acceleron ow pt
bluebird bio cover real competit indic
discuss ip note clinic use brought forward
continu litig settlement like occur across patent holder
technolog februari univers california grant
foundat patent gene edit could still face challeng
licens requir see begley univers california grant long-sought
crispr patent possibl reviv disput broad institut stat news februari
acquisit nightstar foray gene
therapeut see difficulti
later-stag gene therapi think commerci might
challeng week phase trial aducanumab discontinu biogen
announc would acquir nightstar therapeut cash move
provid compani posit gene therapi space specif rare
ophthalm condit gener trend pivot gene therapi highlight
recent move roch acquir spark therapeut novarti acquir avexi
see move long-term hedg gene therapi market acquir platform
could expand multipl indic note current later-stag
indic unlik move revenu needl next year late-stag
asset acquir deal could commerci viabl although expect
blockbust drug asset
acquir later-stag asset nightstar nsr-
rpgr smaller indic patient choroideremia nsr-
patient x-link retin pigmentosa nsr-rpgr
expect addit data nsr-rpgr program first phase
preliminari data trial suffici regulatori approv must
conduct addit phase trial satisfi regul expect top-lin data
program second half think phase data could
enough file regulatori approv estim combin could gener
approxim peak sale nsr-rpgr like gener think
price paid fair note market hardli enough chang growth
profil post-aducanumab preclin asset acquisit could address
larger market given lack clinic data exclud valu
assess transact figur overview nightstar pipelin
figur pipelin acquir nightstar
advantag acquir gene therapi platform current
commerci prospect remain small given histori space
surpris compani step back ophthalmolog gene therapi market
decemb split appli genet corpor agtc
agtc competitor nightstar focus similar asset
concern nightstar center scienc think gene therapi
eye somewhat valid rather small market xlrp
choroideremia note spark luxturna use retin dystrophi first
approv gene therapi sale anem best also
understand peopl age incid ophthalmolog condit increas
argument support deal note less like
genet relat incid wet age-rel macular degener
wamd market address regeneron roch like novarti
technic point view like eye-focus gene therapi platform
easier access direct inject non-invas monitor lower viral load treat
dissemin lower potenti wide-rang side effect despit advantag
think commerci opportun small
tissu cite manufactur advantag
clinic proof-of-concept choroideremia patient treat show
improv read least letter visual acuiti chart one year vs
untreat popul see figur refer sourc found
data show higher rate vision retent compar night
natur histori studi one year patient receiv lost
letter use visual acuiti chart compar patient untreat group
see figur trend widen month group vs
untreat group
figur phase dataimprov visual acuiti
figur proof-of-concept choroideremia
phase data nsr-rpgr program demonstr interest efficaci
accept safeti profil note patient cohort
patient cohort demonstr earli efficaci signal see figur
refer sourc found compani suspect inflamm may affect
efficaci cohort regardless data earli need see clearer
efficaci signal patient fulli comfort program
compani current enrol phase dose expans studi addit phase
studi like requir regulatori registr
year natur histori eye ist high dose year natur year eye gainon year ist high dose year natur month eye gaintwo year charl martineau univers toronto
figur phase data nsr-rpgr studi xlrp
collabor voyag therapeuticsgen therapi
parkinson friedreich ataxia
neurocrin foray gene therapi recent sign collabor agreement
voyag therapeut januari neurocrin voyag enter
collabor agreement develop gene therapi potenti treat pd
friedreich ataxia fa neurocrin paid voyag up-front cash
equiti invest access vy-aadc pd fa think
anoth smart busi develop invest diversifi pipelin still
stay core neurolog focu seen littl data specif gene
therapi product asid phase trial publish annal
neurolog link deal repres lower-risk entri point gene therapi
program expect next key data point includ updat enrol
phase clinic trial pd first patient decemb updat
inform candid select program fa
deal specif asid up-front financi commit neurocrin
neurocrin respons fund clinic develop vy-aadc
complet phase trial voyag option co-
commerci asset neurocrin us cost profit share
arrang ou voyag would elig mileston royalti ou sale
voyag could also grant neurocrin full global commerci right exchang
mileston payment royalti
deal also call neurocrin fund develop
phase clinic trial similar pd program voyag option co-
commerci us cost profit split voyag could also
grant neurocrin full ww commerci right exchang mileston payment
royalti base global sale sanofi option commerci fa
program ou term also call neurocrin fund develop two addit
patient db improv loci month charl martineau univers toronto
potenti mileston royalti rate
aadc program develop mileston
us royalti mid-teen thirti percentag net sale
 ou royalti low-teen twenti percentag net sale
fa program develop mileston
us royalti low-teen high-teen percentag net sale
 ou royalti high-singl digit mid-teen percentag net sale
addit discov program
us royalti high-singl digit mid-teen percentag net sale
 ou royalti mid-singl digit low-teen percentag net sale
aggreg commerci mileston collabor product
total
vy-aadc detail initi clinic data potenti opportun goal gene
therapi restor aadc aromat l-amino acid decarboxylas enzym activ
improv levodopa sensit hope also improv clinic motor function pd
loss neuron critic aadc enzym midbrain produc dopamin
lead progress loss motor function less respons levodopa see
figur role aadc enzym pd
data phase trial suggest neural administ gene therapi
abil improv amount on-tim time patient experi
troublesom dyskinesia overal qualiti life figur figur key
earli clinic data appear support gene-therapi clinic benefit
patient diagnos year rel advanc diseas also
found shift diseas progress interest indic might help
significantli slow diseas therapi address believ
toxic accumul alpha-synuclein like impact progress
physic symptom figur inde see drug compet
anti-alpha-synuclein approach rather like complimentari also
signific reduct levodopa-equival dose reduct cohort
month reduct cohort year increas cohort year
due singl patient
figur chang time per
figur qualiti life improv
figur shift diseas progress
safeti yv-aadc look accept especi given sever diseas
patient invas therapi administr voyag note
follow regard safeti profil yv-aadc
surgic procedur success complet patient phase trial
infus well toler vector-rel sae
patient discharg hospit within day follow surgeri
one patient experi two saesa pulmonari embol relat heart arrhythmia
patient treat anti-coagul complet resolut
sae
determin sae caus immobl
surgic procedur dvt prophylaxi ad surgic protocol
follow event subsequ event observ
phase trial design trial random double-blind
placebo-control evalu efficaci vy-aadc patient trial
motor
clinicaltri gov entri found detail trial includ
medic manag
fluctuat
popul parkinson diagnosi year adequ respond
oral medic hour time
random design patient random either one-tim administr
vy-aadc total dose vector genom placebo surgeri
primari endpoint time without troublesom dyskinesia good time
measur self-report patient diari month endpoint
secondari endpoint diari time motor function qualiti life
patient global function measur
proport particip improv clinic global impress
score also includ non-motor symptom safeti
biomark data vy-aadc putamin coverag aadc enzym express
activ pet scan chang patient daili dose oral levodopa
current includ direct valuat vy-aadc program
includ assum return dcf given interest phase data
program comfort neurocrin invest pd program
fa opportun earlier lead candid select expect
note current avail treatment modifi diseas progress
accord neurocrin approxim patient us experi
symptom onset year life expect year patient
genet defect reduc product frataxin protein exact role
protein remain unclear thought help regul iron transfer cell
mitochondria without enough frataxin energi mitochondria aka cell
powerhous fall caus cell damag
program aim deliv function fxn gene restor frataxin level
least normal relev neuron cardiac myocyt voyager/neurocrin
use believ novel bbb penetr capsid optim deliveri
transduct system therapi therapi allow potenti administr affect
tissu heart progress phase clinic program support
interest pre-clin data knockout mous model diseas
innov sourc revenu
examin broader biopharma sector believ biosimilar
continu disrupt legaci innov busi much
current revenu opportun biosimilar player ou market think
next year us opportun like materi product approv
launch
coverag univers two compani expand biosimilar busi amgen
via samsung bioepi jv think posit stronger
rel much broader approach biosimilar
product across immunolog oncolog rare diseas vs anti-tnf portfolio
pursu commerci ww wherea current plan
europ wholli own biosimilar franchis wherea share
profit via samsung bioepi joint ventur inde think amgen biosimilar
busi help maintain grow revenu base face current revenu
eros biosimilar franchis impact
figur view biosimilar franchis vs biosimilar
repres innov sourc revenu tradit innov biotech
current opportun remain ou us opportun come could help
polici chang seen disrupt biosimilar us
growth slowthi like due rebat bundl prevent formulari
placement janssen protect remicad patent thicket prevent launch
 abbvi humira seen disrupt legaci
busi name neupogen neulasta epogen biosimilar yet take
end think rebat elimin outlin section drug
price js strategi shown anticompetit biosimilar could start make
seriou dent innov sale also expect sale acceler follow settlement
 launch amjevita
biosimilar business- key driver address declin
current base busi declin think amgen emerg
biosimilar busi could key revenu driver analysi
biosimilar busi becom signific driver commerci busi
ip expir transpar around patent disput threat
biosimilar impact part base-busi biosimilar could one
answer revenu declin
see biosimilar franchis provid grow long-term cash flow help
replac matur brand face competit view well-suit execut
base strong experi develop commerci biolog
combin success patent litig addit compani divers
product line could support extend time-to-market delay litig
flexibl offer competit discount increas payer coverag
tailwind biosimilar busi includ
larg grow market biolog evid origin sale
 anti-tnf leverag multipl indic
potenti first line statu
feel amgen strategi invest biosimilar also make sens macro-
level biosimilar potenti sustain less sensit price
legisl featur import healthcar industri move toward
biosimilar could drive signific upsid like grab share
market develop biosimilar compet market share brand
drug account origin product sale compani six
late-stag biosimilar drug either approv develop figur six
biosimilar repres potenti market addit early-stag
biosimilar develop repres market point see
near-term opportun europ eu sale vs us due histor
friendlier environ biosimilar approv greater clariti patent disput
howev imbal geograph market share even us patent overhang
resolv model eu share biosimilar sale
driven growth amjevita us potenti sale septemb settlement
grant amjevita biosimilar humira patent licens begin sell drug
biosimilar alreadi market europ includ amjevita kanjinti
biosimilar herceptin receiv approv eu us mvasi
biosimilar avastin assum potenti launch regulatori file
eu us recent complet abp biosimilar remicad expect
potenti bsufa approv commerci launch like follow
complet phase trial januari evalu abp biosimilar rituxan
mild-to-moder rheumatoid arthriti trial met primari endpoint current
anoth abp phase trial non-hodgkin lymphoma on-going expect
conclud conserv estim launch abp account
data analysis/prepar bla submiss month approv process
abp amgen biosimilar eculizumabposs way captur
alexion pnh ahu busi develop biosimilar orphan
indic pose differ challeng vs larger indic ra psoriasi
signal point commit potenti biosimilar eculizumab note
compani current engag phase clinic trial europ pnh patient
see link recent file ipr challeng three recent grant patent
soliri cover composit matter formul method treatment pnh
signal could hint compani plan eventu pursu regulatori
approv biosimilar eculizumab even alexion abl convert patient
ultomiri could opportun lower price altern european countri
typic open biosimilar competit current assum
biosimilar eculizumab could launch europ patent
issu us biosimilar like unless ipr success
 patent licens begin ra trial complet on-going non-hodgkin estimate complet alexion lost
eu patent litig extend patent
biosimilar help drive revenu growth light erod legaci base
busi amjevita mvasi sale boost franchis model biosimilar
grow compound-annual-growth-rate vs consensu figur driven better
expect growth amjevita biosimilar adalimumab follow settlement
allow us entri earli also assum greater sale
biosimilar due increas confid compani abil commerci
asset versu competitor humira repres largest share biosimilar
market henc project biosimilar sale come amjevita
project equal contribut kanjinti herceptin biosimilar abp
remicad biosimilar abp rituxan biosimilar mvasi avastin
biosimilar abp soliri biosimilar repres sale due
smaller market uncertainli around ip face eros base
busi particularli enbrel howev believ biosimilar franchis provid
signific cash flow support matur base busi support pipelin
figur bullish amgen biosimilar cs vs consensu
model biosimilar use histor sale drug origin
start point forecast volum growth base popul rate assum
biosimilar take percentag origin sale year increas market
penetr percentag increas significantli patent origin drug
expir growth slow sever year market matur assum
price discount origin market model kanjinti herceptin abp
remicad amjevita humira abp rituxan abp soliri
assum po unapprov biosimilar model higher po phase asset
phase trial need prove non-inferior statu origin
competit advantag develop manufactur varieti biolog
asset view strong track record develop drug win
regulatori approv success commerci
hous
manufactur compani commerci asset intern pipelin
develop late stage asset acquir highlight leader
manufactur biolog critic compon success commerci
biosimilar addit elig full econom sale biosimilar
unlik competitor must share sale jv partner samsung
histori success litig ip iron abl limit competitor
seek enter market prior patent expir due compani skill
litig ip note compani patent case defend enbrel
ariad pharmaceut coheru bioscienc held
sandoz bring approv enbrel biosimilar market past sever year
current wait verdict furthermor court recent upheld two patent
repatha sanofi praluent biosimilar front note
also settl humira allow commerci amjevita come
us success win patent case give us greater convict
navig complex ip landscap requir success commerci biosimilar
biogen biosimilar businessmor limit scope profit split
jv partner samsung biolog
biosimilar busi leverag biolog develop commerci
knowhow howev must share profit jv partner similar
also focus develop effort biosimilar howev unlik biogen
fewer asset must share profit samsung biolog via joint ventur
entiti samsung bioepi own scope
biosimilar busi limit anti-tnf vs much broader oncolog rare diseas
focu current develop plan samsung bioepi develop
commerci biosimilar infliximab adalimumab etanercept speak
samsung bioepi commerci asset outsid us think
us could provid attract opportun plan commerci
asset us exclud sale get clariti still estim
peak end-us sale could easili exceed vs end-us sale
biosimilar portfolio see figur biosimilar build figur
forecast base busi vs biosimilar
figur biogen biosimilar forecast eu
figur biogen contribut biosimilar
fiscal year end anti-tnf biosimilar revenu eu salesbenepali biosimilar enbrel growth biosimilar remicad growth biosimilar humira growth unadjust biosimilar growth share samsung jv profit base busi biosimilarsbas excl biosimilarsbasebusi charl martineau univers toronto
per commerci agreement ink agre commerci
three anti-tnf europ also benepali japan book sale
asset product revenu compani also recogn expens
associ sale market sg line item applic royalti payment
mainli sale imraldi includ cog line main
share profit loss relat commerci agreement recogn
collabor profit/loss share line item assum sale
market expens associ biosimilar busi approxim
lower compani sg expens sale product cost
good fulli book sale revenu earn impact
significantli blunt account profit-shar samsung biolog see figur
view biosimilar franchis versu consensu
see benefit headwind biosimilar busi benefit
capac develop commerci large-molecul drug notabl
tysabri
rel easi lower-risk cash flow need spend level
develop innov molecul
start alreadi demonstr success actual cash flow
still see downsid biosimilar busi
space get crowd multipl player drive net price
requir competit contract novartis/sandoz
must share profit jv partner samsung biolog
case novartis/ sandoz
us launch plan current portfolio product compani
fulli rule note us commerci current
current portfolio limit anti-tnf miss opportun
oncolog rare diseas
bundl tactic innov molecul manufactur stymi growth
biosimilar like subsid next year point on-going
litig janssen/ regard potenti anti-competit contract
janssen essenti prevent payer provid offer lower cost
biosimilar remicad argu janssen/ engag contract tie
rebat janssen product inclus remicad exclus biosimilar
provid opt lower cost biosimilar janssen rebat risk
would put provid financi risk asid highlight issu
current rebat system us also highlight potenti tactic innov
use prevent competit entri biosimilar august district court
eastern district pennsylvania deni jnj motion dismiss anti-trust civil lawsuit
brought remicad contract watch case close
better understand emerg legal think around rebat contract
competit tactic exclud biosimilar sale
revoc rebat safe harbor could also jeopard sort tactic
use broad rebat prevent formulari posit biosimilar think
polit remov rebateswhich could help get biosimilar
formulari manufactur origin molecul would forc lower list price
biosimilar compet would much transpar environ
would allow contract structur base rebat alon actual product cost would
decid factor believ race bottom model
price cut small share biosimilar think healthi fair
competit could help propel use biosimilar us
fda also address issu anem biosimilar competit juli
action plan link fda document subsequ comment former fda
commission scott gottlieb identifi biosimilar uptak slow due
rebat program bundl state growth biosimilar
anem consolid across suppli chain made
attract manufactur pharmaci benefit manag group purchas
organ distributor split monopoli profit lucr volume-
base rebat refer biologicsor bundl biolog
productsrath embrac biosimilar competit lower price
patent thicket essenti biolog protect hundr patent
delay biosimilar entri yearswith product protect
multipl decad post initi launch
note fda identifi clear problem protect innov biolog
agenc offer concret plan beyond support market competit
reduc game fda requir attempt unfairli delay market
competit follow-on product fda help provid expedit review
approv biolog court lawmak prevent anti-
holt analysi support macro
second conserv market impli expect healthcar
sub-industri second attract valuat shown figur
holt market impli expect indic futur level return capit cfroi
requir justifi today valuat market expect green dot
consensu forecast pink bar indic upsid potenti stock
unless secular/cycl declin long term market price
consensu
rank base spread forecast market-impli cfroi
conserv attract demand
figur market-impli expect benchmark rel healthcar
holt len click see us healthcar industri holt
return capit cfroi histor forecast market-impli healthbiotechnologyhealth distributorspharmaceuticalshealth health serviceslif sciencestool serviceshealth equipmenthealth techhealth facilitieshealth suppliescfroi year mediancfroi lfycfroi consensu forecast ntm market impli cfroi conserv expect current price impli declin return demand expect current price impli increas return healthbiotechnologyhealth distributorspharmaceuticalshealth health serviceslif sciencestool serviceshealth equipmenthealth techhealth facilitieshealth suppliesposit spread currentneg spread charl martineau univers toronto
histor valuat vs healthcar
accord holt aggreg econom yield us biotech never cheap
rel us healthcar past year
figur show holt econom yield us rel us healthcar
holt econom yield proxi oper free cash flow yield invers holt
econom pe higher yield indic cheaper valuat question regard
sustain futur cash flow
us biotechnolog histor trade premium healthcar lower yield
howev sinc becom rel cheaper spread today year
figur holt econom yield us biotech vs us healthcar weight aggreg
holt len click see us healthcar industri holt
holt capit deploy trend assess show gilead activ
 seem deploy excess cash share
buyback compani coverag deploy cash
figur show capit deploy trend past year total across
figur capit deploy trend total cash deploy
holt len click see us healthcar industri holt
holt uniqu proprietari methodolog compani analysi stock select
deliv object global consist view compani
proprietari holt methodolog correct subject interpret account
standard convert incom statement balanc sheet inform
econom return call cfroi return invest close
holt valuat methodolog base discount cash flow framework
number distinguish featur includ uniqu way calcul termin valu
firm cost capit
holt lenstm web-bas platform allow investor easili compar compani
sector region access holt insight histor compani perform market
expect risk consider includ esg risk
contact credit suiss sale repres want learn holt
gain access holt lenstm
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
medic meet
also avail formatpleas ask
start endconferenceloc liver transplant societytoronto psychiatr associ annual meetingsan francisco societi endocrinolog ece lyon societi cardiolog esc heart failur congressathen atherosclerosi societi congressmaastricht societi clinic psychopharmacologyscottsdal societi cellular therapi melbourn american societi clinic oncolog annual meetingchicago societi colon rectal surgeonscleveland academi allergi clinic immunolog congresslisbon congress gastrointestin cancerbarcelona diabet associ san francisco academi dermatolog venereolog eadvmilan european leagu rheumat annual congressmadrid renal associ european dialysi transplant associ budapest european hematolog associ amsterdam clinic immunolog societiesboston societi microbiolog microb meetingsan francisco societi stem cell researchlo angel american societi retina specialist chicago european academi neurologyoslo societi thrombosi haemostatsi isth melbourn headach societyphiladelphia associ intern confer aaic lo angel aid societi mexico citi societi cardiolog esc world congress cardiologypari weekla vega societi retina specialist euretina pari scientif sessionsnew orlean confer lung cancerbarcelona colleg neuropsychopharmacolog copenhagen retina societi annual meetinglondon committe treatment research multipl sclerosisstockholm cancer conferencebrussel failur societi americaphiladelphia societi therapeut radiolog oncologychicago associ studi diabetesbarcelona societi paediatr endocrinologyvienna societi bone miner researchorlando congress parkinson diseas movement disordersnic european societi medic oncolog barcelona respiratori societi madrid cancer immunotherapi conferencenew york muscl societycopenhagen infecti diseas weekwashington hemophilia foundat anaheim colleg reproduct medicinephiladelphia neurolog associ st loui societi geneticshouston colleg chest physiciansnew orlean societi anesthesiologistsorlando european gastroenterolog weekbarcelona neurosci chicago american cystic fibrosi conferencenashvil charl martineau univers toronto
start endconferenceloc weekla vega immunotherapi cancer nation harbor associ respiratori carephoenix societi nephrolog kidney week washington colleg allergi asthma immunologyhouston colleg rheumatolog acr atlanta american associ studi liver diseas boston academi ophthalmolog san francisco cancer therapi intern symposiumdublin heart associ aha scientif sessionsphiladelphia neuro-oncolog sno phoenix trial alzheim diseas confer ctad san diego research organis genit infect epilepsi societi baltimor societi hematolog orlando societi cell biologywashington colleg neuropsychopharmacologyorlando antonio breast cancer symposiumsan antonio symposium endovascular therapi iset hollywood cancer symposium aga astro sso san francisco colleg nuclear medicine/ societi nuclear medicinetampa storag diseas network world symposiumorlando fibril symposiummadrid cancer symposium astro suo san francisco aha american stroke associ intern stroke conferencelo angel glaucoma societi oxon hill american academi pain medicin annual meetingn harbor committe treatment research multipl sclerosi actrim forumwest palm beach asian pacif associ studi liver diseasebali retrovirus opportunist infect croi boston academi allergi asthma immunolog aaaai philadelphia toxicolog annual meet sot anaheim academi dermatolog aad denver nation comprehens cancer network annual conferenceorlando intern societi nephrolog world congressabu dhabi colleg cardiolog chicago societi annual meet endo san francisco societi gynecolog oncolog annual meet women cancertoronto vaccin congresswashington lung cancer congress elcc geneva colleg medic geneticssan antonio congress clinic microbiolog infecti diseas eccmid pari associ orthopaed medicinewashington associ cancer research san diego congress obstetrician gynecologist annual meet acog seattl kidney foundationnew orlean academi neurologytoronto research vision ophthalmolog arvo baltimor societi pediatr hematology/ oncolog annual meet fort worth associ immunologistshonolulu societi gene cell therapi annual meet asgct boston societi cataract refract surgeri ascr boston american thorac societi intern congressphiladelphia diseas week san diego feder hemophiliakuala lumpur congress painamsterdam charl martineau univers toronto
also avail formatpleas ask
figur upcom catalyst
lead companycoverag compani relationshiptherapeut areadrugindicationdescriptiontim frameimportancenovartisbiogenneurologiczolgensmasmapdufa bla approvalmay ruxolitinib gvhd steroid-refractori acutepdufa solid tumor target cell lung cancerphas clinic data solid tumor bite target psma- hle prostatephas clinic data solid tumor bite target psma prostatephas clinic data solid tumor inhibitor soft tissu sarcoma wt clinic data bite target bcma multipl myeloma mm phase clinic data solid tumor oral kra solid tumor kra mutat phase clinic data target acut myeloid leukemia aml phase clinic data solid tumor bite glioblastomaphas clinic data solid tumor bite target hle small cell lung cancerphas clinic data allphas data present data present dlbclphase data present allergi phase artemi full data june rhinosinus w/ nasal polypspdufa sbla approv treatmentdata phase alldata phase studi ruxolitinibvitiligophas data readout upcom medic adren hyperplasiafda meet adult pivot healthrelugolixuterin fibroidsphas top line data liberti diseasephas long-term data solid tumor libtayocutan squamou cell carcinomaema regulatori decis studi combin cystic top-line combin cystic fibrosismolecul select nda osteoperosischmp opinion myeloma mm phase mecarbilheart failurephas enrol small molecul inhibitor alsphas trial choroideremiaphas full enrol allergi submiss allergyphas trial antibodi migrainephas top line enbrel tnf-a inhibitor multiplejudg decis court case vs osteoperosisema solid tumor kanjinti biosimilar breast cancerbsufa court decis praluent rochebiogenneurologicrisdiplamsmaphas rainbowfish trial sclerosishead-to-head data vs healthelagolixuterin fibroidssnda diseasenda file gene-edit sca first patient fibrosisfda approv age combin cystic fibrosisnda approv wamdoct combin cystic fibrosisful data potenti nacfc sclerosisfda filgotinibrheumatoid arthritissubmiss phase capsid inhibitor hiv treatmentdata phase nrti hiv treatmentdata phase syndromephas readout proof readout proof cell lymphomadata registr studi allcomplet enrol phase trial diseaseremdesivirebola viruscomplet enrol phase trial diseasevesatolimod curecomplet phase adren hyperplasiaphas initi healthrelugolixuterin fibroidsphas top line data liberti therapi nash treatmentphas readout atla diseasedescovyhiv prevent prep snda approv prioriti filgotinibpsoriat arthritisiniti phase dlbclcomplet enrol pivot trial mab data phase studi phase studi healthlinzagolixuterin fibroidsphas top line data primros dermatitisphas pediatr year old top allergi fda advisori committe biosimilarabp biosimilar infliximab immunologybsufa supranuclear palsi psp phase potenti pivot top line rochebiogenneurologicrisdiplamsmanda file rochebiogenneurologicrisdiplamsmaema filgotinibrheumatoid arthritisupd fda solid tumor capmatinibnon-smal cell lung cancernda submiss novarti treatment-nav acutetoplin data readout ruxolitinib gvhd steroid-refractori acutetoplin data readout ruxolitinib gvhd steroid-refractori chronictoplin data readout baricitinib atop dermatitisphas data breeze-ad like solid tumor pemigatinibcholangiocarcinomaphas data like esmo solid tumor pemigatinibcholangiocarcinomanda submiss adren hyperplasiapivot trial announc fibrosisema submiss age small molecul target initi clinic datal target lipoprotein dyslipidemia hypercholesterolemiaphas top line datal enrol complet late enrol complet navig late pdufadec charl martineau univers toronto
figur upcom catalyst
lead companycoverag compani relationshiptherapeut areadrugindicationdescriptiontim frameimportancebiohavenamgenneurologicrimegep zydi odtmigrainenda mab lupu cle sle phase top data anti-tau alzheim sphase top line ruxolitinibvitiligophas initi biosimilarabp biosimilar rituximab nhlphase top line data small molecul target myeloid leukemia aml phase initi clinic bite target myeloid leukemia aml phase updat clinic bite target myeloma mm phase initi clinic data bite target hle acut myeloid leukemia aml phase initi clinic bite target bcma- hle multipl myeloma mm phase initi clinic solid tumor imlyg oncolyt viru melanomaphas initi clinic alspivot trial cohort vixotrigin trigemin neuralgiaphas trial treatment-nav chronictri initi solid tumor pemigatinibtumor agnosticphas trial initi healthlinzagolixendometriosisphas trial diseasecomplet phase trial ataxialead candid allergyphas top data top data studi high-dos formul studi phase potenti lymphomainiti studi phase potenti studi phase small molecul antitrypsin deficiencyclin develop second gene-edit beta-th updat initi recruitment/ pain mechanismpain non opioid initi clinic next-gen corrector cystic fibrosisphas proof-of-concept studi follow bunionectomyphas dose rang studi qd regimen cystic fibrosisphas proof-of-concept studi allergi pdufa approv age healthlinzagolixuterin fibroidsphas top line data primros healthrelugolixendometriosisphas top line data spirit healthrelugolixendometriosisphas top line data spirit dermatitiseu regulatori decis rhinosinus w/ nasal polypseu regulatori obstruct pulmonari diseaseproof-of-concept studi filgotinibulc coliti uc data select phase sclerosismylan ipr decis patentearli ruxolitinibatop dermatitisphas data readout earli combin cystic fibrosisfda approvalearli natalizumab epilepsyphas top data filgotinibankylos spondylitisiniti phase solid tumor mage enrol phase nhldata registr studi data phase studi dlbclcomplet enrol pivot phase allergi chmp opinion anti-lingo multipl sclerosisphas top-lin healthelagolixuterin fibroidssnda approv combin cystic fibrosis regulatori submiss filgotinibcrohn diseasecomplet enrol divers phase allergi ema target alpha-synuclein parkinson diseasephas top data alsphas top line choroideremiaphas top line intrathec diseasecilofexor enrol phase vixotrigin small fiber neuropathyphas top data late cia phase top-lin datal plasminogen activ strokephas top data late healthlinzagolixuterin fibroidsnda file late clinic data clinic data filgotinibulc coliti uc phase manta testicular safeti trial read tumorsiniti clinic studi allogen solid anal merkel cell top-line data readout podium solid tumor parsaclisiblymphoma multipl initi data solid tumor pemigatiniburotheli cancertoplin data solid tumor pemigatiniburotheli cancersnda diseasenda approv commerci solid tumor target small cell lung cancerphas initi clinic datatbdlowamgenamgenoncolog solid tumor bite hle gastric cancerpre-clin data tbdlowamgenamgenheme-onc bite target hle acut myeloid leukemia aml phase initi clinic datatbdlowamgenamgenheme-onc bite target lymphoblast leukemia phase initi clinic datatbdlowamgenamgenoncolog solid tumor bite hle gastric cancerpre-clin data aso alsphas top line clinic advanc announcementtbdlowbiogenbiogenophthalmologynsr-rpgrx-link retin pigmentosaphas top line datatbdmediumnovartisbiogenneurologiczolgensmasmareach trial start comer tbdlowregeneronregeneronrespiratorydupixentcopdphas top datatbdmediumregeneronregeneronrespiratorydupixentasthmaphas pediatr year old top linetbdmediumregeneronregenerongidupixenteosinophil esophag eoe phase readouttbdmediumregeneronregenerononcolog solid tumor libtayobas cell carcinomaphas top data tbdmediumregeneronregenerononcolog solid tumor libtayocerv cancerphas top datatbdmediumregeneronregenerononcolog solid tumor libtayonsclc phase top charl martineau univers toronto
term definit sourceacceler approv fda approv nda bla basi surrog vs clinic endpoint manufactur typic requir conduct post-market studi show drug clinic benefit real world confus prioriti review acceler approv noth time take fda review bla nda fdaactiv controlclin trial design use activ compar determin new drug better current avail diseas csadvisori committe meetingadvisori committe provid fda independ advic outsid expert issu relat human veterinari drug vaccin biolog product medic devic food gener advisori committe includ chair sever member plu consum industri sometim patient repres addit expert special knowledg may ad individu committe meet need although committe provid advic agenc fda make final decis fdaallogenictissu cell obtain individu self-donor csantibodi drug conjugatea class highli potent biopharmaceut drug compos antibodi link via chemic linker biolog activ drug cytotox compound acr reviewautolog tissu cell obtain genet similar ident donor csbiolog licens applic bla vehicl drug sponsor formal propos fda approv new pharmaceut sale market appli biolog drug csbiologic/ larg moleculetherapeut modifi natur occur biolog compound monoclon antibodi csbiosimilara biolog similar anoth biolog medicin known refer product alreadi licens food drug administr fda regulatori author product highli similar refer product term safeti puriti potenc may minor differ clinic inact compon phrmabispecif antibodya type antibodi bind two differ antigen time bispecif antibodi studi imag treatment cancer made laboratoryncibreakthrough therapi design fda breakthrough therapi design process design expedit develop review drug intend treat seriou condit preliminari clinic evid indic drug may demonstr substanti improv avail therapi clinic signific endpoint drug receiv btd elig follow fast track design intens guidanc effici drug develop program fda organiz commit involv senior managementfdabsufabiosimilar user fee act act congress author fda collect fee compani fund biosimilar drug approv process bsufa date typic date fda indic make decis approv biosimilar drug fda-tchimer antigen receptor t-cell type treatment patient cell type immun system cell chang laboratori attack cancer cell cell taken patient blood gene special receptor bind certain protein patient cancer cell ad laboratori special receptor call chimer antigen receptor ncicatalystkey event data read action potenti impact valu stock cschmpcommitte medicin product human use chmp ema committe respons conduct initi assess eu-wid market author applicationsemacombin therapytherapi use multipl drug combin csconfid intervala rang valu defin specifi probabl valu paramet lie within dictionarycomplet respons letter letter issu fda complet full review nda bla indic drug question approv market indic defici nda bla fdadata top lineclin trial data releas compani pertin detail may includ primari endpoint notat trial success full data usual present scientif forum csdoubl blindclin trial design provid patient know patient receiv activ drug placebo fdaemaeuropean medicin agenc european regulatori bodi overse drug develop approv emaexclus criteriacriteria would exclud patient particip clinic trial cs track fda track process design facilit develop expedit review drug treat seriou condit fill unmet medic need purpos get import new drug patient earlier track address broad rang seriou condit elig acceler approv prioriti review addit roll review fdagen therapygen therapi introduct remov chang genet materialspecif dna rnainto cell patient treat specif diseaseamerican societi gene cell therapygener gener drug brand name drug dosag safeti strength taken qualiti perform intend use term typic refer small molecul drug biosimilar charl martineau univers toronto
term definit sourcehatch-waxman actform known drug price competit patent term restor act act establish approv pathway gener drug product applic submit abbrevi new drug applic also grant day exclus certain anda applic act also grant exclus innov drug typic year post patent expir fdainclus criteriacriteria patient must meet includ clinic trial csindic diseas appropri patient group drug intend treat accord pi/ label fdainvestig new drug ind applicationregistr new drug fda permit clinic test determin safeti efficaci human patient fdainvestig choiceclin trial design investig get decid drug use typic part combin investig asset activ comparison arm csmonoclon antibodya type protein made laboratori bind substanc bodi includ cancer cellsncimonotherapytherapi use singl drug csmulti-armclin trial design meant test multipl dose combin drug placebo control activ control csnew drug applic nda vehicl drug sponsor formal propos fda approv new pharmaceut sale market appli small molecul biolog drug fdanew molecular/ chemic entitya new small molecular drug product never approv fda fdanh nation service- england public bodi overse budget plan deliveri public health care england uk nhsopen labelclin trial design provid patient know patient treat activ drug csorphan drug design design fda provid orphan statu drug biolog defin intend safe effect treatment diagnosi prevent rare diseases/disord affect fewer peopl affect person expect recov cost develop market treatment drug fdapdufaprescript drug user fee act act congress author fda collect fee compani fund drug approv process pdufa date typic date fda indic make decis nda bla fdapi/ labelpackag insert/ prescrib inform formal document fda indic approv usag drug also includ key safeti inform clinic data use approv product fdapipelinetherapeut develop compani csplacebo controlledclin trial design use placebo control determin effect drug vs activ control csprimari endpointth primari object clinic trial may one primari endpoint refer co-primari endpoint csprioriti review fda expedit review nda bla target complet date within six month applic accept fda fdaprior review vouchervouch issu fda allow prioriti review bla nda -- regardless design previous award voucher issu compani develop drug rare pediatr diseas neglect tropic diseas voucher expir transfer sold parti fdarar diseasediseas impact less individu us csroll reviewa drug compani submit complet section biolog licens applic bla new drug applic nda review fda rather wait everi section nda complet entir applic review bla nda review usual begin drug compani submit entir applic fdafdartf refuse-to-fil letter issu fda accept bla nda review issu within day bla nda file explain fda accept applicationfdasblasupplement biolog licens applic formal applic process allow manufactur chang label drug alreadi approv chang label market new dosag strength drug chang way manufactur drug compani must submit supplement new drug applicationfdasecondari endpointth secondari object clinic trial may one secondari endpoint cssmall moleculetherapeut chemic compound pill exampl small moleculescssndasupplement new drug applic formal applic process allow manufactur chang label drug alreadi approv chang label market new dosag strength drug chang way manufactur drug compani must submit supplement new drug applicationfdastandard review fda normal review nda bla target complet date within ten month applic accept fda fdastatist significanceth likelihood relationship two variabl caus someth chanc clinic trial design p-valu less consid statist signific dictionaryuk unit kingdom nation institut excel provid nation guidanc advic improv health social care uk charl martineau univers toronto
overview drug develop process
figur overview drug develop process
step discoveri developmentstep pre-clin researchstep clinic researchstep regulatori reviewstep post-launch monitoringinvestig drug applicationnew drug applicationnovel compound synthes lab settingdrug undergo anim test assess safetydrug undergo human test safeti efficacyhealth agenc conduct thorough review data packag make approv decisionhealth agenc monitor safeti use publicphas trial healthi volunt peopl diseasepurpos safeti dosagelength sever monthslarg trial peopl diseasepurpos efficaci safetylength sever month yearslarg trial peopl diseasepurpos efficaci charl martineau univers toronto
figur drug develop cost stage process
stagesurviv rate project stageaverag per phase perproject number projectsp stagetot includ project failur durat per project yr capit launch charl martineau univers toronto
compani mention price
